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ABSTRACT
DNA double-strand breaks (DSBs) are major DNA lesions that when repaired 
unfaithfully can give rise to loss of genetic information, chromosomal rearrange-
ments such as insertions/deletions (indels) and copy number alterations (CNAs), 
which in turn lead to genomic instability that is characteristic of almost all cancer 
types. In this context, it is thought that genomic instability has critical roles in 
cancer initiation, progression and intra-tumor heterogeneity (ITH). DSBs have 
also been exploited for genome-editing purposes where using different CRISPR 
(clustered regularly interspaced short palindromic repeats) systems, one can create 
DSBs in the target DNA to alter sequences and modify gene function. However, this 
approach is not without drawbacks, as DSBs can be created at sites other than the 
intended target (known as off-target effects), which can potentially be mutagenic. 
Therefore, given the importance of DSBs in genomic instability, their role in genera-
tion of CNAs and genome-editing technologies, it is of great interest to determine 
genomic locations of DSBs and their frequency along the genome, together with 
DNA copy number profiling. Thus, the focus of this thesis was to develop molecular 
tools for detection and quantification of DSBs with single-nucleotide resolution 
in different model systems, in combination with the development of technologies 
for DNA copy number profiling, by which we can collectively understand the 
biology behind DSBs, their links to CNAs in the context of cancer and assess the 
safety profile of CRISPR systems for therapeutic applications.
In Paper I, we developed BLISS (Breaks Labeling In Situ and Sequencing) as a 
quantitative method enabling genome-wide DSB profiling. We showed that BLISS 
accurately identified both endogenous and drug-induced DSBs genome-wide, even 
in samples of a few thousand cells and in single tissue sections. Additionally, we 
demonstrated that BLISS is a powerful tool to measure the off-target activities 
of Cas9 and Cpf1 CRISPR systems, and indeed we found that Cpf1 was more 
specific than Cas9. 
In Paper II, using BLISS-generated DSB data from cell lines, we modeled the 
contribution of genetic and epigenetic features in shaping the cancer fragility, and 
made predictions of the frequency of expected breaks across the human genome. 
We constructed random forest regression models from four DSB datasets and found 
that the most influential feature in DSB frequency prediction is replication timing 
across all models. In addition, we noticed that open chromatin at transcriptionally 
active genes and associated regulatory factors have the largest influence on the 
frequency of DSBs than transcription per se.
In Paper III, we developed CUTseq, which builds on the design of BLISS from 
Paper I, and can be used for gDNA barcoding and amplification to generate 
multiplexed DNA sequencing libraries for performing reduced representation 
sequencing of DNA samples extracted from cell lines, FFPE tissue sections or 
small sub-regions thereof. We demonstrated the applicability of CUTseq for CNA 
profiling, and showed that CUTseq can reproducibly detect a considerable  fraction 
of high-confidence single nucleotide variants (SNVs) that were also detected by 
a standard exome capture method. Finally, we demonstrated that CUTseq can 
be applied for multi-region tumor sequencing to assess ITH of CNA profiles of 
multiple-small regions of a single FFPE tissue sections of primary and metastatic 
breast cancer lesions.
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11 INTRODUCTION
1.1 Role of DNA double-strand breaks (DSBs) in 
genomic instability 
Constant maintenance of the genome sequence information and structural integrity 
is crucial for faithful transmission of genetic material to daughter cells1. However, 
aberrations are inevitable as the DNA molecule is subject to a multitude of dif-
ferent types of damage on a daily basis2. Examples include DNA mismatches, 
oxidative and hydrolytic cleavage, DNA-protein cross-links, and various forms 
of breaks such as single-strand breaks (SSBs) and double-strand breaks (DSBs)1. 
The latter constitute the most significant threat to the cell, as if not repaired or 
miss-repaired they can result in loss of genetic information, cell death or structural 
and quantitative chromosomal rearrangements, collectively known as structural 
variations (SVs)3. SVs are rearrangements of large DNA segments including inser-
tions/deletions (indels), duplications, inversions and translocations3, which in turn 
can lead to genomic instability4,5. Genomic instability, which refers to a state of 
increased mutations and copy number changes, and is characteristic of almost all 
cancer types, is thought to play a critical role in cancer initiation, progression and 
also as a driver of intra-tumor heterogeneity (ITH)6. Regardless of their causes, 
elevated levels of DSBs contribute to genomic instability and therefore, properly 
repairing DSB lesions is indispensable for maintaining the stability and integrity 
of the genome. In the following sections, I will explain the most common sources 
of DSB formation, repair systems and links to the generation of copy number 
variations (CNVs), and lastly the technologies that can be applied to detect DSBs. 
1.2 Sources of DSBs 
DSBs have been classically associated with exposure to exogenous toxic agents, 
such as ultraviolet light, X-ray, ionizing radiation and certain chemotherapeutic 
drugs, such as etoposide7. However, the majority of DSBs are thought to form 
during fundamental physiological processes7.
Reactive oxygen species (ROS)
ROS, which are generated as by-products of cellular metabolism can oxidize 
nucleobases of DNA, thus resulting in both SSBs and DSBs7,8. In addition, onco-
genic activation can lead to increased levels of ROS, which in turn oxidize dNTPs 
and result in the occurrence of replication stress and the formation of DSBs9. 
Furthermore, accumulation of ROS have been reported to induce lesions and strand 
breaks on mitochondrial DNA, resulting in mitochondrial DNA degradation10,11, 
which in turn causes mitochondrial dysfunction12.
2Antibody diversification and meiotic recombination 
In the immune system, during the development of B cells to create antibody diver-
sification, class-switch recombination (CSR) and V(D)J rearrangements are associ-
ated with transient induction of DSBs by the activation-induced cytidine deaminase 
(AID) and recombination activating genes (RAG1/RAG2), respectively13,14. AID 
converts cytidine into uridine, and the resulting mismatch is recognized by the 
cellular repair system that converts it to DSBs and re-joins them15. The RAG1/2 
complex with its endonuclease capacity can also induce DSBs that are promptly 
recognized by the repair machinery16. In addition, during meiosis, initiation of 
homologous recombination and proper segregation of sister chromatids is medi-
ated by SPO11 in complex with other proteins to generate transient DSBs, which 
are subsequently detected by the cellular repair systems17,18. 
DNA replication
In proliferating cells, replication stress (i.e., slow down or stalling of replication 
forks) is thought to be the main source of DSB formation19. Replication stress can 
happen due to different reasons including: i) lack of factors essential for DNA syn-
thesis (e.g. dNTP, DNA polymerases, replication origin firing)20; ii) decoupling of 
DNA polymerase-helicase activity; iii) obstacles impeding fork progression (e.g. 
abasic sites, inter/intra strand crosslinks, non-canonical secondary structures like 
hairpins/quadruplexes and hard to replicate regions such as repetitive telomeric/
centromeric sequences)21,22 and iv) collisions with the transcription machinery20,23. 
Transcription process
A growing body of evidence supports the idea that physiologic transcription is also 
a major source of endogenous DSBs and a potential cause of DSB-related muta-
tions24. Transcription can lead to DSBs in several ways. For example, collision of 
transcription and replication machineries in a head-on or co-directional fashion, 
can lead to stalling/displacement of RNA polymerase and of the replication fork25. 
In addition, head-on collisions induce the formation of R-loops – special three-
stranded nucleic acid structure, composed of DNA-RNA hybrid and the associated 
non-template single-stranded DNA26 – leading to fork stalling and DNA breaks27. 
Moreover, non-template single-stranded DNA exposed in R-loops is more vul-
nerable to break by the formation of noncanonical structures such as hairpins and 
G-quadruplexes, which increase the chance of replication stress and genomic 
instability28. Transcription activation itself is associated with the formation of 
transient DSBs inside gene regulatory regions, such as promoters and enhancers, 
mostly as a result of type II DNA topoisomerases (TOPII), that generate transient 
DSBs to help resolve torsional stress linked with transcription fork movements 
and enhancer promoter interactions29,30.
3Intrinsic fragile genomic regions
Certain genomic regions are naturally prone to break. DSBs can occur at higher 
frequency in regions known as common fragile sites (CFSs) and early replication 
fragile sites (ERFSs). These two types of fragile hotspots represent distinct classes 
of fragility, each with features that may contribute to their instability. CFSs occur 
primarily in late-replicating genomic loci that contain large genes with AT-rich 
sequences and poor density of replication origins. CFSs largely show cell-type speci-
ficity and often overlap with the boundaries of cancer-associated CNAs, particu-
larly large deletions20. In contrast, ERFSs occur in early-replicating DNA regions, 
rich in GC sequences, replication origins and actively transcribed genes31. ERFs 
also overlap with recurrent chromosomal rearrangements and CNAs, especially 
with the large duplications and translocations found across many cancer types31. 
Programmable DSBs in genome editing 
DSBs can be experimentally exploited in such a way that specific sites of the DNA 
can be targeted for genome editing purposes. Clustered regularly interspaced short 
palindromic repeats (CRISPR) is a hallmark of the adaptive immune system in 
many bacteria and most archaea, by which CRISPR-derived RNA in combina-
tion with different Cas (CRISPR associated) endonuclease proteins – that act like 
molecular scissors – induce DSB in the nucleic acids of the invading viral or  plasmid 
DNA, leading to its dysfunctionality32. CRISPR is a specialized region of DNA 
containing short repetitive base sequences separated by stretches of interspersed 
variable sequences known as spacers. These short spacer sequences are acquired 
from previous exposure to foreign genetic material that was incorporated into the 
CRISPR region, which then serve as a memory to enable bacteria to recognize the 
viruses and defend future attacks32. This system can be repurposed when CRISPR 
components are transferred into other, more complex organisms, such as mammalian 
cells, and as such the DNA sequence of interest can be targeted and cut for gene 
manipulation/editing33.
Since type II CRISPR systems use single-component effector proteins, such as Cas9, 
the system has been successfully harnessed for genome editing in  eukaryotic cells 
by introducing the three essential components of the system together: Cas9, crRNA 
(CRISPR RNA), and tracrRNA (Trans-activating CRISPR RNA)34. Alternatively, 
crRNA and tracrRNA have been fused to create a chimeric single-guide RNA 
(sgRNA), enhancing the simplicity and the possibility to multiplex and edit several 
regions at the same time35. Typically, the first 20 nucleotides of the sgRNA are 
complementary to the target DNA, followed by the PAM (Protospacer Adjacent 
Motif, which is used as a recognition handle for Cas proteins to bind to for the 
cleavage process) sequence, which in the case of the Cas9 system is normally an 
NGG-rich sequence at the 3’ end of protospacer sequence (where N is any nucleo-
tide). Although the development of the CRISPR/Cas9 system for genome editing 
4was revolutionary, especially in mammalian cells, off-target cleavage events of 
the system have become a major concern over recent years36. Hence, there have 
been tremendous efforts made into seeking ways to improve cleavage  specificity, 
including sgRNA modifications, engineered versions of Cas9, searching for 
enzymes with higher specificity, and several other approaches37. Recently, another 
CRISPR-Cas system has been identified and named Cas12a/Cpf1 (CRISPR from 
Prevotella and Francisella bacterial species). Cas12a has several new features when 
compared to Cas938, which broadens its applications for genome engineering. In 
this system, only a short single crRNA is required to guide the cleavage process, 
which makes the system simpler than Cas9. In addition, Cas12a uses a T-rich PAM 
at the 5’ end of the protospacer sequence as a target DNA recognition sequence in 
order to generate DSBs with 5’ overhangs of 4-5 nucleotides at the distal site of the 
PAM38. Cas12a has also been successfully harnessed for human genome editing, 
but as discussed earlier despite the advantages of CRISPR toolboxes, off-target 
mutagenesis is still a major concern36.
1.3 DNA damage response (DDR) 
DSBs must be properly repaired regardless of their sources, because of the lethal 
consequences that arise from their formation, which result in genomic instability 
and the potential onset of diseases such as cancer. To safeguard genome stability, 
an efficient network of tightly regulated cellular pathways to sense, signal, and 
ultimately repair the lesions, referred to as DNA damage response (DDR), exists in 
different organisms1. DNA damage is sensed by proteins Mre11, Rad50 and Nbs1 
(MRN complex), which lead to activation of protein kinases that initiate cascades 
of signaling pathways involved in the DDR. The central regulators that orchestrate 
signaling in the mammalian DDR are ataxia-telangiectasia-mutated (ATM) and 
ataxia telangiectasia and Rad3-related (ATR) kinases39. ATM is primarily activated 
upon sensing of DSBs, whereas ATR responds predominantly to SSBs, and to a 
lesser extent to DSBs and other types of damage, yet there is cross-talks between 
ATM and ATR39. Upon DSB sensing, ATM and ATR become activated and phos-
phorylate Ser/Thr-Glu motifs in hundreds of proteins, including Ser139 of H2A.X 
(γH2A.X) histone variant40. In turn, γH2A.X recruits repair proteins to the DSB41, 
leading to the activation of pathways that eventually slow down or arrest cell 
cycle progression, providing enough time for repair proteins to resolve the DNA 
damage or trigger apoptosis if the damage is irreparable42. The DDR network is 
crucial for maintaining genome integrity, hence any mutation in a component of 
the system poses a major threat to the cell that may lead to the onset of pathologi-
cal disorders. For example, germline mutations in the ATM gene are linked to the 
development of an autosomal recessive disorder known as ataxia-telangiectasia 
5(A-T), a progressive neurodegenerative disorder associated with cerebellar ataxia, 
immunodeficiency, cell-cycle checkpoint defects, genome instability and cancer 
predisposition43. Mutations in the ATR gene cause Seckel syndrome, which is 
characterized by intrauterine-growth retardation, dwarfism, microcephaly, and 
skeletal and brain abnormalities44. 
1.4 DSBs repair pathways 
To avoid catastrophic consequences of DSBs, two major repair mechanisms are 
in place: non-homologous end joining (NHEJ) and homologous recombination 
(HR), which are separately summarized in the following paragraphs.
Non-homologous end joining
In NHEJ, the two ends of a DSB are quickly re-joined45. NHEJ is the major mecha-
nism for DSB repair in human cells46 and is believed to be the key repair pathway 
involved in V(D)J and CSR recombination during B and T lymphocyte develop-
ment47. NHEJ is active in several phases of cell cycle, but it is the dominant DSB 
repair mechanism in G0 and G1. When NHEJ is initiated, the two DSB ends are 
recognized and bound by a heterodimeric Ku protein complex, containing Ku70 
(XRCC6) and Ku80 (XRCC5) polypeptides48. Ku is known to have  extraordinary 
affinity for DSB ends in a sequence-independent manner, and acts as a  scaffold 
to which other NHEJ proteins are recruited48. The Ku complex recruits the cata-
lytic subunit of DNA-dependent protein kinase (DNA-PKcs) to the two DSB 
ends, resulting in activation of  DNA-PK at the DSB ends49,50. DNA-PK binding 
helps Ku to slide down the DNA duplex and prevent exonucleolytic degradation 
of the DSB ends51. DNA-PK phosphorylates Ser139 on histone variant H2A.X 
(γH2A.X), which recruits the repair machinery to the DSB sites, and, as such, it 
serves a marker for DSBs detection52. DNA-PK also phosphorylates and changes 
the function of other NHEJ factors, including Artemis, X-ray cross complement-
ing protein 4 (XRCC4), XRCC4-like factor (XLF), Aprataxin-PNK-like factor 
(APLF), and DNA ligase IV (LigIV), which accumulate at DSBs to rejoin the 
broken ends53. It had been thought that recruitment of NHEJ repair proteins is a 
sequential stepwise model, whereas recent studies suggest that the order of repair 
factors can be flexible based on the complexity of the damage54. Given the fact 
that the type of nuclease, polymerase and ligase that are involved in the NHEJ 
pathway can act on a wide range of DNA ends with different conformations, NHEJ 
is a relatively error-prone process, which can lead to the accumulation of small 
insertions, deletions and translocations at the re-joined ends55. 
6Homologous recombination (HR)
The second most important DSB repair mechanism that enables more precise 
repair of DSBs is HR. While NHEJ is active in several phases of the cell cycle, 
HR is active mainly in S and G2 phases, where a homologous template is avail-
able56. HR is initiated by the binding of the MRN complex to the DSB ends. The 
5´ ends of the DSB are processed to create single-stranded DNA 3´-OH overhangs, 
during a process known as resection. Recombinases Rad51 or Dmc1 have been 
shown to be the key players that bind to the created ssDNA overhangs to form 
the presynaptic filament (i.e. a helical filament of recombinase enzyme on ssDNA 
in preparation for strand invasion)57. The presynaptic filament is needed to guide 
the ssDNA to the homologous duplex DNA and form the synaptic complex that 
searches for homologous sequences. Once found, the ssDNA 3´end invades the 
homologous sequence (known as strand-invasion process) in the duplex,  creating 
a DNA joint called a D-loop, which is then extended through DNA synthesis. 
After strand synthesis, the D-loop is altered into a cross-like structure known as a 
Holliday junction. From this step onward, the two primary repair pathways have 
been described for HR: i) the double-strand break repair (DSBR) pathway, also 
known as double Holliday junction model; and ii) the synthesis-dependent strand 
annealing (SDSA) pathway58. In DSBR, the 3´-OH overhang that was not involved 
in strand invasion, invades the homologous duplex DNA to form another Holliday 
junction. Finally, the junctions are resolved by nicking nucleases, through which, 
based on how the Holliday junctions are resolved, the decision as to whether chro-
mosomal crossing-over should occur is determined. In the SDSA pathway, there 
is no crossing-over of recombinant products, and the newly synthesized 3´ end 
of the invading strand is released from the Holliday junction, and through base-
pair complementarity it anneals to the ssDNA on the other break end that was not 
involved in strand invasion process58. Any gap between the newly annealed strands 
is filled by ligation to finalize the damage repair. The NHEJ and HR pathways 
are tightly regulated to ensure that undamaged genetic material is transferred to 
daughter cells. Therefore, deficiencies and mutations in any components of these 
repair pathways endanger genome integrity, and potentially lead to the onset of 
pathological disorders, including cancer59. 
1.5 Adverse outcomes of DSB repair and structural 
changes
Improper repair of DSBs can give rise to SVs (i.e., genomic alterations as small 
as 50 base pairs reaching up to megabases in length) that involve balanced rearrange-
ments such as translocations and inversions or imbalanced rearrangements (quan-
titative changes) such as duplications and deletions, also known as copy number 
variations (CNVs, in germline cells) or copy number alteration (CNAs, in somatic 
7cells)60,61,62. Genomic SV is a major source of variation between human population, 
underlying human evolution and many diseases from developmental disorders to 
cancer63. 
Two major mechanisms have been reported to be involved in the formation of 
SVs: non-allelic homologous recombination (NAHR) and NHEJ63. NAHR is a 
form of HR and occurs between highly similar non-homologous DNA sequences 
and is thought to be the major source of SVs formation based on the observation 
that the boundaries of SVs are often found near repetitive sequences, mainly low 
copy repeats (LCRs)64. LCRs are tracts of duplicated DNA sequences of between 
1-300 kb in length that have a sequence similarity of more than 95%, so that 
their misalignment during mitosis or meiosis generates rearrangements such as 
deletions, duplications and translocations65. It was suggested that LCRs act as a 
substrate for NAHR, by which most of the recurrent SVs arise64, that share a com-
mon size, clustered breakpoints (i.e., breakpoints that fall in the same genomic 
region), and recur in different unrelated individuals. In the case of occurrence of 
DSBs in genomic regions lacking extensive homologous sequences that can be 
used as repair templates for NAHR, ends of DSB are processed by NHEJ instead, 
which often leads to insertions and deletions at breakpoints. NHEJ is proposed 
as the cause of non-recurrent SVs that differ in sizes in each individual and show 
distinct breakpoints65,66. 
It has been reported that SVs may contribute to tumor development by different 
mechanisms. For example, they can have direct consequences through alteration 
of the gene dosage (e.g., duplication of oncogenes or deletion of tumor suppressors 
genes), and creation of oncogenic fusion proteins by translocations. In addition, 
SVs can also have indirect outcomes, such as the reorganization of the proximity 
distance of regulatory elements (e.g., active enhancers) and proto-oncogenes, thus 
leading to cancer-related gene overexpression67–70.
As discussed above, DSBs can be generated from normal cellular physiological 
processes (e.g., replication, transcription), and are involved in the formation of 
SVs/CNAs that threatens genomic stability, and are also exploited by genome-
editing technologies. Therefore, precisely mapping the location and frequency of 
DSBs along the genome is of great interest for better understanding the biology of 
DSBs, genome fragility, and specificity of genome editing tools. Hence, several 
methods have been developed for genome-wide detection of these lesions and used 
in different applications ranging from studying the dynamics of DSBs in DNA 
damage, to measuring the off-target activity of genome-editing nucleases. Here, 
we review the most commonly used DSB detection methods. 
81.6 Methods for genome-wide profiling of DSBs
1.6.1 Chromatin immunoprecipitation and high-throughput 
sequencing (ChIP-seq)
In ChIP-seq71 , using specific antibodies targeting DNA-associated proteins one 
can study the interaction of a protein of interest with DNA [Fig. 1]. ChIP-seq 
was adopted to detect recruited repair proteins such as γH2A.X at DSB locations, 
to study fragile sites in yeast and DSB repair processes in mammalian cells as 
well72,73. It has also been exploited for genome-wide profiling of off-target bind-
ing activities of CRISPR Cas systems, by detection of DNA repair factors (e.g., 
MRE11)74 upon DSB induction or using catalytic deactivated Cas9 (dCas9), 
which stably binds to DNA once it has recognized its target site 75. Although, 
ChIP-seq proved to be capable of detecting DSBs and identifying different off-
targets depending on sgRNAs, however, using antibodies targeting the activated 
DNA repair proteins makes ChIP-seq an indirect method for DSBs detection. In 
addition, as normally repair factors are not localized to the immediate vicinity of 
DSB and instead extended to a large chromatin region (up to 1 Mb) around it, 
ChIP-seq cannot provide nucleotide resolution. Furthermore, applying ChIP-seq 
for genome-wide off-target profiling of CRISPR systems, using dCas9 may not 
be ideal, as its deactivation can affect its binding specificity. 
Figure 1. In ChIP-seq cells are fixed by formaldehyde to cross-link proteins and DNA. 
1) A bead-labeled antibody targeting protein of interest at DSB site is introduced. 2) Using 
a magnet, the antibody-protein-DNA complex is immunoprecipitated. 3) Cross-links are 
removed, DNA is extracted and sequencing adapters are ligated to the DNA fragments. 
4) Library is ready to be sequenced to find out which DNA fragment was bound to the 
target protein.
9To overcome these limitations, several other genome-wide methods for DSBs 
detection have been developed, which can be divided into two main categories; 
i) those that can map unrepaired DSBs or exposed DNA ends; and ii) those capable 
of mapping repaired DSBs.
Unrepaired-DSB mapping methods
1.6.2 Breaks labeling enrichment on streptavidin and next-
generation sequencing (BLESS)
BLESS76 was the first method developed for direct genome-wide DSB detection. In 
BLESS, cells containing endogenous or induced DSBs are cross-linked with formal-
dehyde, lysed and briefly incubated with proteinase K in order to purify intact nuclei. 
Next, DSBs are blunted, 5′-phosphorylated and the DSB ends are in situ labeled by a 
short hairpin-like proximal biotinylated adapter and enriched on streptavidin beads. 
The captured DSBs are ligated to another hairpin-like distal adapter, polymerase 
chain reaction (PCR) amplified using primers binding to proximal and distal adapt-
ers and finally subjected to high-throughput sequencing [Fig. 2]. 
Figure 2. BLESS detects DSBs in fixed materials. 1) Cells are fixed by formaldehyde; 
intact nuclei are isolated, DSBs are in situ blunted and biotin-labeled oligonucleotide 
(adapter) is introduced. 2) Adapter is ligated to DSB ends. 3) Labeled DSB fragments are 
enriched by streptavidin beads. 4) Another adapter (distal) is ligated to the free extremity 
of labeled DSBs. 5) Adapter loops are released by I-SceI endonuclease and fragments are 
PCR amplified. 6) Samples are subjected to high-throughput sequencing. 
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The in situ nature of the method with no need of introducing oligonucleotide into 
the living cell, lack of dependency to the NHEJ pathway, and capability of detect-
ing DSBs in tissue samples treated by in vivo delivery of Cas9 in mice77, are some 
of the BLESS features. However, as the method works on fixed material, it can 
only detect DSBs that are not repaired at the time of fixation. Cell fixation per se 
may also be a source of inducing artificial DNA damage and breaks78 although, 
a recent study reported that DSB signals obtained from both non-fixed and fixed 
samples were similar with very low noise levels79. In addition, having a PCR step 
for DSB amplification can also introduce biases. Furthermore, BLESS needs more 
than 106 cells as starting material and the protocol proved to be labor intensive. To 
overcome these limitations, we therefore aimed to improve this method, which is 
the core part of this doctoral thesis.
1.6.3 Double-strand break capture (DSBCapture)
DSBCapture80 in principle follows BLESS workflow but with the introduction 
of A-tailing (adding a non-templated nucleotide to the 3’ end of blunted DSBs) 
to increase the efficiency of ligation of BLESS adapters to DSB ends, and also 
addition of the Illumina RA5 adapter sequence directly into the BLESS adapter 
[Fig. 3]. By these changes, the authors reported an increased ligation efficiency 
that led to higher sensitivity of DSB detection compared to BLESS. DSBCapture 
was able to detect DSBs induced by EcoRV in HeLa cells, AsiSI system in U2OS 
cells – i.e., an engineered cell line, known as DIvA that relies on the expression of 
the AsiSI restriction enzyme, which upon 4-hydroxytamoxifen treatment induces 
about a hundred DSBs, where the method detected 74 out 100 most γH2AX-
enriched sites. In addition, DSBCapture was used for endogenous DSBs detec-
tion in normal human epidermal keratinocyte cells, where 4.5-fold more DSBs 
compared to BLESS were found. Furthermore, the authors reported that DSBs 
were enriched at regulatory and G-rich regions. Despite the fact that DSBCapture 
improved BLESS detection sensitivity, however, similar to BLESS, capturing only 
unrepaired DSBs, the need of high number of starting materials and also having 
a labor-intensive protocol are some of its limitations. 
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Figure 3. DSBCapture is based on the BLESS workflow for detection of DSBs, but with the 
introduction of an A-tailing step. Cells are fixed by formaldehyde, intact nuclei are isolated, 
DSBs are in situ blunted and 1) 3’ end of DSB fragments are A-tailed. 2) Biotin-labeled 
oligonucleotide (adapter) is introduced. 3) Adapter is ligated to DSB ends. 4) Labeled DSB 
fragments are enriched by streptavidin beads. 5) Another adapter (distal) is ligated to 
free extremity of labeled DSBs. 6) Adapter loops are released by I-SceI endonuclease and 
fragments are PCR amplified. 7) Samples are subjected to high-throughput sequencing.
1.6.4 End Sequencing (End-seq)
END-seq81 also follows the design of BLESS and DSBCapture, but with the dif-
ference that cells are embedded in low-melting agarose plugs, lysed, and DSBs are 
ligated without any fixation process. END-seq also introduced an A-tailing step 
– adding a non-templated nucleotide to the 3’ end of blunted DSBs – to increase 
the ligation efficiency of DSB-tagging adapter, in addition to incorporation of the 
Illumina RA5 adapter sequence into the adapter [Fig. 4]. Using this method, the 
authors were able to monitor DSBs that were induced by AsiSI restriction enzyme, 
zinc-finger-nuclease (ZFN) and RAG endonuclease. END-seq in principle can also 
be used for specificity profiling of CRISPR systems. In comparison to BLESS, a 
greater number of DSBs were detected by End-seq at individual cleavage sites. 
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In addition, the authors estimated the sensitivity of the method as to be able to 
detect one DSB in 10,000 cells, while the sensitivity of BLESS and DSBCapture 
was not reported. Despite the fact that in this method cells are not fixed, however 
a long incubation time of embedded cells in agarose plugs before DSB ligation 
(i.e., 1 hour at 50 °C, then for 7 hours at 37 °C, followed by storage at 4 °C) may 
itself be a source of artificial DNA damage and breaks81. Similar to BLESS and 
DSBCapture, the need for high-input samples, capturing only exposed DNA ends 
that are not repaired, being labor intensive and challenging on tissue samples are 
some limitations of END-seq. 
Figure 4. End-seq is also based on the BLESS workflow for detection of DSBs, but is per-
formed in living cells. 1) Living cells are embedded in an agarose plug, lysed, DSBs are in 
situ blunted and 3’ end of DSB fragments are A-tailed. 2) Biotin-labeled oligonucleotide 
(adapter) is introduced. 3) Adapter is ligated to DSB ends using a ligase enzyme. 4) Labeled 
DSB fragments are enriched by streptavidin beads. 5) Another adapter (distal) is ligated to 
free extremity of labeled DSBs. 6) Adapter loops are released by I-SceI endonuclease and 
fragments are PCR amplified. 7) Samples are subjected to high-throughput sequencing.
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1.6.5 iBLESS and qDSB-seq 
Recently, these two new DSB detection methods aimed to further improve the 
original BLESS and End-seq protocol. iBLESS79 was used in yeast models and 
tried to avoid fixation of cells by embedding them in agarose beads (they claimed 
that the efficiency of reagents diffusion is more than agarose plugs that was used 
in End-seq). In parallel, authors also compared different fixation procedures and 
showed that DSB signals obtained from both non-fixed and fixed samples were 
similar with very low noise levels. In addition, to improve the sensitivity of the 
method, the authors explored a variety of experimental parameters (e.g., duration 
of fixation and proteinase K conditions), and reported that intensive proteinase 
K treatment for overnight at 50 °C with gentle fixation (2% formaldehyde for 5 
minutes) is crucial for reducing background signal. iBLESS showed to be able to 
capture DSBs induced by BamHI restriction enzyme (1,620 sites out of 1,667 were 
detected), and several other enzymes that create different kinds of dsDNA ends 
(i.e., NotI, AsiSI, SrfI and I-SceI). iBLESS reported the sensitivity of detecting a 
single DSB per 100,000 cells, which is higher than End-seq (i.e., 1:10,000). On 
the downside, the use of agarose beads requires a large amount of material (2x10 
9 cells), which is a major obstacle79. 
qDSB-seq82 was essentially developed to bring accurate quantification power to any 
sequencing-based DSB labeling method, though so far it has only been  applied for 
BLESS (in DIvA cells) and iBLESS (yeast cells). In qDSB, a “spike-in”  strategy 
was introduced to BLESS/iBLESS protocols through inducing low-frequency 
DSBs at known loci using site-specific restriction enzymes, which allows for the 
calibration of BLESS/iBLESS data, and to calculate the absolute frequency of 
DSBs per cell. The quantification of qDSB-seq is based on the proportion of reads 
originating from induced and studied DSBs. The method was used for quantifica-
tion of Top1-dependent DSBs at natural replication fork barriers, DSBs induced 
by radiomimetic drug and replication stress. qDSB-seq showed to be accurate, 
stable, robust and claimed to be potentially applicable in combination with any 
genome-wide DSB labeling method.
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1.6.6 In vitro Cas9-digested whole genome sequencing 
(Digenome-seq)
Digenome-seq was originally developed for profiling off-target activity of CRISPR 
systems [Fig. 5]. Its strategy is to identify the insertions and deletions (indels) 
made by in vitro Cas9/Cpf1 cleavage of purified DNA, followed by whole-genome 
sequencing (WGS)83,84. In vitro digestion on cell-free DNA provides the advantage 
that the method is not limited to cell-based factors such as chromatin. In addition, 
the lack of need for PCR amplification before WGS and the ability of multiplexing 
for off-target detection of several sgRNA at the same time shows the progression 
of Digenome-seq. One major limitation of the method is the high cost of WGS. 
In addition, as the technology lacks the enrichment strategy for cleavage sites, all 
of the non-cleaved sequences are also sequenced, which causes increased back-
ground noise reads. Furthermore, in vitro digestion does not consider the presence 
of chromatin and the 3D structure of nucleus that may affect the cleavage, repair 
and, specificity of RNA-guided nucleases.
Figure 5. Digenome-seq is an in vitro assay to find on/off-target sites of nuclease-induced 
DSBs. 1) Purified genomic DNA is subjected to nucleases to create DSBs. 2) Sequencing 
adapters are ligated. 3) Whole-genome sequencing is performed for  analysis of insertions 
and deletions made by nucleases.
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1.6.7 CIRCLE-seq
This method was developed to improve the high background noise of Digenome-
seq. In CIRCLE-seq85, gDNA is sheared and circularized though intramolecular 
ligation. Then Cas9 cleavage site within the circularized DNA molecule is cut by 
Cas9, making it linearized and creating new DNA ends for ligation of sequenc-
ing adapter [Fig. 6]. CIRCLE-seq proved to substantially reduce the background 
noise by enrichment strategy for sequencing cleaved gDNA and requirement of 
low-sequencing depth (only 4-5 million reads).
Figure 6. CIRCLE-seq workflow: 1) purified gDNA is randomly sheared to average length 
of 300 bp. 2) Fragmented DNA is circularized by intramolecular ligation and the remaining 
undesired linear DNA molecules are degraded away by exonuclease treatment. 3) Circularized 
DNA molecule containing Cas cleavage site (red) is linearized by in vitro Cas treatment, 
which creates newly cleaved DNA ends. 4) The ends are ligated to sequencing adapter, PCR 
amplified and 5) subjected to pair-end sequencing. 
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Repaired-DSB detection methods
1.6.8 Integrase defective lentiviral vector (IDLV)
This in vivo method is amongst the earliest based on tagging the DSBs generated 
by specific nucleuses with double-stranded integrase defective vector, which gets 
trapped into the broken DNA through the NHEJ-repair pathway. Labeled DSBs are 
then enriched by LAM-PCR (Linear amplification–mediated PCR) using primers 
specific to long terminal repeats (LTRs) of vector and finally subjected to high-
throughput sequencing [Fig. 7]. Using this method, several reports showed the 
ability of IDLV for detection of zinc finger nucleases (ZFN), transcription activator-
like effector nuclease (TALEN) and CRISPR/Cas9 nucleases off-target sites 86,87. 
As a method that can in vivo label DSBs through integration of viral vector, makes 
it a good choice for monitoring the DSBs generation and repair processes that 
occur in living cells. However, dependency on NHEJ repair pathway, transfec-
tion efficiency, possible integration of IDLV at varying distanc from actual break 
sites, low detection frequency and high costs are some of the IDLV limitations. 
Figure 7. IDLV capture is based on in vivo integration of IDLV vector into DSBs sites. 
1) IDLV is introduced into living cells. 2) It is then captured into DSB sites through NHEJ. 
3) Labeled DSB is enriched by LAM-PCR using primers specific to LTRs. 4) The sample 
is subjected to high-throughput sequencing.
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1.6.9 Genome-wide unbiased identification of DSBs enabled by 
sequencing (GUIDE-seq)
In this in vivo technology that was also developed for detection of off-targets of 
CRISPR systems, a small end-protected and blunted double-stranded oligode-
oxynucleotide (dsODN) is incorporated in vivo through NHEJ-mediated pathway 
to DSBs that are generated by Cas9. The tagged DSBs are PCR amplified and 
subjected to high-throughput sequencing88[Fig. 8]. Guide-seq proved to be a very 
sensitive method by detecting off-targets occurring at the frequency of 0.1% or 
lower in a cell population. Although, this method has been used frequently for Cas9 
off-target detection, transfection efficiency of dsODN into the cells, dependency 
to the NHEJ- mediated repair process to incorporate the dsODN, and being chal-
lenging on primary cells and tissue samples are some of GUIDE-seq limitations.
Figure 8. Guide-seq is an in vivo based assay for on/off target detection of DSBs formed by 
nucleases. 1) In living cells, DSB is induced by nuclease of interest and then double-stranded 
oligodeoxynucleotide (dsODN) is introduced to living cells. 2) dsODN is incorporated 
to DSB site through NHEJ-mediated capture. 3) Labeled DSB is amplified using dsODN 
 specific primer and sequencing adapters are ligated. 4) Prepared library is subjected to 
high-throughput sequencing.
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1.6.10 Linear amplification–mediated high-throughput genome-
wide translocation sequencing (LAM-HTGTS)
HTGTS method was initially invented for the detection of translocation events upon 
DSB induction89. The strategy is based on in vivo induction of DSB in a known 
genomic region by nucleases, and uses this DSB as a “bait” that translocate to another 
DSB from another genomic region as a “prey”. The translocated junction is then 
PCR-amplified and exposed to high-throughput sequencing. Using this method, the 
authors were able to show that DSBs have a tendency to translocate with regions 
that are actively transcribed89. Recently, LAM-HTGTS [Fig. 9], an improved ver-
sion of HTGTS by introducing linear amplification strategy has been applied for 
CRISPR/Cas9 off-target detection through chromosomal translocation between 
the on-target (bait) and off-target (prey) DSBs. The translocated junction is then 
linearly amplified by known primer to bait sequence, and a library is prepared for 
high-throughput sequencing90. LAM-HTGTS method confirmed the off-target sites 
detected by Guide-seq, yet with additional sites identified unique to LAM-HTGTS. 
However, as the occurrence of translocation events induced by Cas9 are scarce, a 
large input sample is required for their detection. In addition, the influence of 3D 
genome organization biases the translocation frequencies to occur on regions with 
close nuclear proximity, by which the frequency of DSBs can be underestimated. 
Figure 9. LAM-HTGTS is an in vivo assay for the detection of DSBs through  translocation 
events of known DSB (bait) with other unknown DSBs (prey). 1) in vivo induction of DSB 
(bait) by nucleases. 2) Translocation of bait DSB with other DSB (prey) in its vicinity. 
3) Translocated DSB fragments are extracted into a tube. 4) Linear amplification PCR 
(LAM-PCR) of translocated junction using biotinylated primer targeting bait DSB and 
 ligation of sequencing adapters. 5) Sample is then subjected to high-throughput sequencing. 
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2 DOCTORAL THESIS
2.1 Aims of the study
As genomic instability is a hallmark of cancers91,92 and given the importance of 
DSBs in driving SVs/CNAs in cancer and their role in genome-editing technologies, 
it is of great interest to have methods that can profile DSBs and CNAs with high 
accuracy and genome-wide scale. The overall aim of this thesis was to develop 
molecular tools for genome-wide detection and quantification of DSBs and 
CNAs in cells and tissue samples, by which we can collectively better under-
stand the biology behind DSBs, assess the safety profile of CRISPR systems 
and investigate how DSBs relate to CNAs.
The specific aims are as follows:
Paper I
• To establish a novel genome-wide technology to precisely map the location 
and frequency of DSBs in low-input samples, and assess its specificity and 
sensitivity.
o Develop Breaks Labeling In Situ and Sequencing (BLISS) to profile 
DSBs in low-input samples
o Verify the versatility of BLISS in a variety of cell models, tissue sections 
and biopsies
o Demonstrate BLISS sensitivity and specificity for detection of induced-
DSBs in known genomic locations using CRISPR systems
• To generate a database of endogenous DSBs occurring in different cancer 
cell types and compare them to CNA breakpoints in tumor 
Paper II
o Apply BLISS technology to widely used normal and cancer cell lines 
that are well characterized by different assays such as DNase-seq, 
Chip-seq, Repli-seq, RNA-seq for genomic and epigenomic features 
(e.g. open chromatin, POL2B & CTCF binding, histone modifications, 
replication timing and gene expression) that have been implicated in 
genome fragility in the Encyclopedia of DNA Elements (ENCODE) to 
construct models that can quantitatively measure how these genomic 
and epigenomic features influence DSB susceptibility  
o  Construct DSB models based on BLISS data from cell lines, compare 
the frequency of DSBs and CNA breakpoints in tumor sequencing 
repositories in order to ask how the generated DSB models relate to the 
pattern of CNAs in different cancers 
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Paper II
• To establish a novel technology for reduced representation genome sequencing 
to characterize CNAs and their heterogeneity in tumor samples
o Develop CUTseq to perform copy number profiling in low-input samples 
o Verify the versatility of CUTseq in a variety of cell models and FFPE 
(Formalin-Fixed Paraffin-Embedded) tissues samples
o Assess DNA CNAs and intratumor heterogeneity of CNAs in primary 
and metastatic breast cancer lesions using CUTseq
The abovementioned aims were addressed in the papers that constitute this thesis 
and the approaches to reach them required multidisciplinary work combining cell 
and molecular biology assays, sequencing and microscopy methods, and bioin-
formatic tools.
2.2 Key methodologies for BLISS and CUTseq
2.2.1 Cells and tissues
For BLISS:
KBM7 cells were obtained from Oscar Fernandez-Capetillo (SciLifeLab, Stockholm, 
Sweden) and cultured in Iscove’s modified Dulbecco’s medium (IMDM, Life 
Technologies, cat. no. 10829018) supplemented with 10% fetal bovine serum 
(FBS, Gibco, cat. no. F2442). U2OS cells were obtained from Prof. Mats Nilsson 
(SciLifeLab, Stockholm, Sweden) and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM, Life Technologies, cat. no. D0819) supplemented with 10% FBS. 
Mouse embryonic stem cells (mESCs) were obtained from Dr. Simon Elsaesser 
(SciLifeLab, Stockholm, Sweden) and cultured in in minimal essential medium 
(MEM, Sigma, cat. no. M2279), supplemented with 20% FBS, 1% GlutaMAX 
(Gibco, cat. no. 35050061), 1% nonessential amino acids (Gibco, cat. no. 11140035), 
1% sodium pyruvate (Gibco, cat. no. 11360070), and 0.2% β-mercaptoethanol, in 
the presence of leukemia inhibitory factor (Sigma cat. no.  L5158-5UG) corre-
sponding to 1,000 U ml–1. HEK 293T cells were bought from ATCC and cultured 
in in DMEM supplemented with 10% FBS. Liver biopsies were obtained from 
wild-type 6-weeks old C57/BL6 male mice sacrificed following the guidelines in 
the MIT protocol #0414-027-17 ‘Modeling and Treating Genetic Disease Using 
Targeted Genome Engineering’ (IACUC AWA #A3125-01, IACUC #0411-040-14, 
approval date 5/16/2013). 
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For CUTseq:
The cell lines were purchased from ATCC: IMR90 (cat. no. CCL-186) cells were 
cultured in MEM (Gibco, cat. no. 10370021) supplemented with 10% non-heat-
inactivated fetal bovine serum (Gibco, cat. no. 16000044), 2 mM L-glutamine 
(Sigma, cat. no. 59202C) and 1% non-essential amino acids (Gibco, cat. no. 11140035); 
A549 (cat. no. CCL-185) cells were cultured in RPMI 1640 (Sigma, cat. no. R8758) 
supplemented with 10% heat-inactivated FBS (Sigma, cat. no. F9665). MCF7 (cat. 
no. HTB-22), HeLa (cat. no. CCL-2) and Caov3 (cat. no. HTB-75) and BT474 (cat. 
no. HTB-20) were cultured in DMEM (Sigma, cat. no. D6429) supplemented with 
10% heat-inactivated FBS (Sigma, cat. no. F9665). SKBR3 (cat. no. HTB-30) cells 
were cultured in McCoy’s 5A (Sigma, cat. no. M9309) supplemented with 10% 
heat-inactivated FBS (Sigma, cat. no. F9665). Cells were maintained in a humidi-
fied at 37 °C containing 5% CO2. All cell lines were tested to be mycoplasma free 
using MycoAlert™ Mycoplasma Detection Kit (Lonza, cat. no. LT07-118). 
FFPE tissues from Turin (TRN samples) of 31 tumor specimens from different 
origin – gastrointestinal stromal tumor (GIST), colon adenocarcinoma (COAD), 
breast invasive carcinoma (BRCA), and melanoma (MELA) – were collected 
at the Pathology Unit of IRCC Candiolo, Italy (ethical permission “Profiling” 
# 001-IRCC-00IIS-10). FFPE tissue sections from Karolinska Institutet (KI  samples) 
were collected from 14 female breast cancer patients – one section of 4 μm thick-
ness per lesion from primary and distant metastases – with ethical permission 
from Karolinska Institutet no. 2013/1273-31/4 with amendment 2013/1739-32.
2.2.2 Sample preparation for BLISS and CUTseq
For BLISS
Cell lines were either grown directly onto 13 mm coverslips (VWR, cat. no. 631-
0148) or spotted onto poly-L-lysine (Sigma, catalogue number P8920-100ML) 
pre-coated coverslips. For CRISPR experiments, HEK293T cells were grown in a 
24-well plate pre-coated with poly-D-lysine (Merck Millipore, catalogue number 
A003E), and finally cells were fixed in paraformaldehyde 4%. For BLISS in tissue 
we used two approaches: 1) Tissue cryopreservation and sectioning, where freshly 
obtained mouse liver biopsies were fixed in 4% paraformaldehyde for 1h at 25 °C, 
then immersed in sucrose gradient (15% overnight and then 30% until the tissue 
sank) before embedding in optimal cutting temperature medium (OCT). Then 
30 μm-thick sections were mounted onto microscope slides, air-dried for 60 min 
at room temperature and stored at 4 °C until processing by BLISS. 2) Obtaining 
nuclei from the biopsies, where freshly extracted mouse liver biopsies were cut 
into small pieces, transferred into a DNA LoBind tube (Sigma, cat. no. Z666548) 
containing nucleus isolation buffer (NaCl 146 mM, Tris-HCl 10 mM, CaCl2 1 mM, 
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MgCl2 21 mM, bovine serum albumin 0.05%, Nonidet P-40 0.2% pH 7.8) and 
gently rotated for 15–40 min until the tissue fragments became transparent. The 
nuclei were centrifuged for 5 min at 500 g, resuspended in 500 μl of 1 × PBS, and 
100 μl of it was dispensed onto a poly-L-lysine (Sigma, catalogue number P8920-
100ML) pre-coated 13 mm coverslip. Nuclei were let to sediment for 10 min at 
room temperature, followed by gentle dispensing of 100 μl paraformaldehyde 8% 
on top of them, which made the final concentration of 4% fixative. Nuclei were 
washed twice in 1 × PBS and stored at 4 °C until further processing.
For CUTseq:
All FFPE tissue sections were deparaffinized by xylene (Honeywell, cat. no. 
534056), followed by immersion in ethanol gradient and hematoxylin-eosin was 
used to stain the sections. The gDNA from different types of samples was extracted 
as follow: 
Cell lines: obtained pellets after trypsinization of cells were washed twice in 1xPBS 
(Ambion, cat. no. AM9625) and lysed using a buffer containing 10 mM Tris-HCl, 
100 mM NaCl, 50 mM EDTA, 1% SDS, 19 mg/ml Proteinase K (NEB, cat. no. 
P8107S), pH 7.5, incubated overnight at 55 °C on a thermomixer, shaking at 800 
rpm. gDNA was purified using common phenol-chloroform extraction protocol, 
quantified using Qubit 2.0 Fluorimeter and High Sensitivity DNA Kit (Agilent, 
cat. no. 5067-4626).
TRN tissue sections: gDNA from five 10 μm-thick sections with more than 50% 
tumor cells were extracted. We obtained 200 ng gDNA after manual dissection 
using the QIAamp DNA FFPE Tissue Kit (Qiagen, cat. no. 56404). Extracted 
gDNA was quantified using Qubit 2.0 Fluorimeter and High Sensitivity DNA Kit 
(Agilent, cat. no. 5067-4626).
KI tissue sections: in order to extract gDNA from multiple small regions 
within a  single FFPE section, we used PinPoint Slide DNA Isolation System™ 
(ZymoResearch, cat. no. D3001), which acts as a glue that is air-dried, peeled off 
and placed into a DNA LoBind tube (Sigma, cat. no. Z666548). The remaining 
parts of the tissue section were also collected as a whole using the same PinPoint 
system into a separate DNA LoBind tube (Sigma, cat. no. Z666548). The tissue is 
then lysed in the same buffer that we used for cell lines, purified using common 
phenol-chloroform extraction protocol and quantified using Qubit 2.0 Fluorimeter 
and High Sensitivity DNA Kit (Agilent, cat. no. 5067-4626). We note that gDNA 
extraction with silica-based kits is also perfectly compatible for cell lines and 
 tissue sections.
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2.2.3 Workflow of BLISS and CUTseq
For BLISS
A detailed step by step protocol has been published in “Nature Protocol Exchange” 
(https://protocolexchange.researchsquare.com/article/nprot-5597). Briefly, fixed 
samples on a solid-surface were permeabilized, incubated for 1 hour in a blunting 
reaction mix (NEB, cat. no. E1201L) at room temperature, followed by in situ 
ligation of double-stranded oligo to DSB ends in a T4 DNA ligase reaction mix 
(NEB, cat. no. M0202M) for 16–18 hours at 16 °C. Next, gDNA is extracted, 
incubated in proteinase K (NEB, cat. No. P8107S) for at least 5 hours at 55 °C 
on a thermomixer, followed by purification. Purified gDNA was sonicated and 
in vitro transcribed using T7 RNA polymerase (ThermoFisher, cat. no. AM1334) 
for 14 hours at 37 °C. Finally, RNA product was used for library preparation by a 
modified Illumina TruSeq Small RNA Library Prep Kit (RS-200-0012).
For CUTseq
A detailed step by step protocol has been published in “Nature Protocol Exchange” 
(https://protocolexchange.researchsquare.com/article/d0ef0512-37b2-461b-9687-
eeec11f167e1). Briefly, extracted gDNA is digested with the restriction enzyme 
HindIII or NlaIII (NEB, cat. no. R3104L or R0125L) for 16–18 hours at 37 °C, 
followed by ligation of CUTseq double-stranded oligo (compatible with staggered 
ends) in a T4 DNA ligase reaction mix (NEB, cat. no. M0202M) for 16–18 hours 
at 16 °C. Ligated gDNA was cleaned up, sonicated and in vitro transcribed using 
T7 RNA polymerase (ThermoFisher, cat. no. AM1334) for 14 hours at 37 °C. 
Finally, RNA product was used for library preparation by a modified Illumina 
TruSeq Small RNA Library Prep Kit (RS-200-0012).
2.2.4 Cas or Cpf1 expression constructs and transfections 
(For BLISS)
We used plasmids containing the spCas9 and sgRNA cassette targeting EMX1 
locus (5′-GAGTCCGAGCAGAAGAAGAAgGG-3′) and VEGFA gene locus 
(5′-GGTGAGTGAGTGTGTGCGTG tGG-3′). The same expression vector was 
used to clone AsCpf1 and LbCpf1 together with their cognate sgRNA for direct 
comparison of these nucleases. For transfection, 24-well plates were coated 
using poly-D-lysine (Merck Millipore, catalogue number A003E) and cells were 
seeded at a density of ~125,000 per well and grown for 16-18h to reach 60-70% 
confluency. Once cells were ready, a mix of 2 μl of Lipofectamine 2000 (Life 
Technologies, catalogue number 11668019) and 500 ng of Cas9/Cpf1 plasmids in 
100 μl of OptiMEM (Gibco, catalogue number 31985062) was used for each well.
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2.2.5 Immunofluorescence, Hematoxylin-eosin staining, imaging 
and automated cell counting 
For BLISS:
Immunostaining of DSB marker γH2A.X was performed using a mouse anti-
phospho-histone H2A.X (ser139) primary antibody (Millipore, catalogue number 
05-636) diluted 1:1000 in blocking buffer – 3% BSA with 0.1% Tween-20 – and a 
goat anti-mouse IgG (H+L) conjugated with Alexa Fluor 647 (Thermo, catalogue 
number A-21235) secondary antibody diluted 1:1000 in blocking buffer. Stained 
γH2A.X foci were imaged every 0.4 μm using Z stack module to cover entire  volume 
of nuclei by a × 40 oil objective and an LSM 780 confocal microscope (Zeiss). 
To count γH2A.X foci we used custom-made scripts implemented in MATLAB. 
For CUTseq:
All tissue sections for this study were deparaffinized by xylene (Honeywell, cat. 
no. 534056) followed by immersion in ethanol gradient. Hematoxylin-eosin was 
used to stain 35 FFPE breast cancer sections that were used for multi-region tumor 
sequencing. Each tissue section was scanned by Eclipse Ti inverted wide-field 
fluorescence microscope (Nikon, Japan) using in phase contrast mode with 10X 
objective. In order to count the number of cells captured for gDNA extraction from 
the tissue region, 16 independent different breast cancer FFPE tissue  sections were 
stained by 1ng/ul Hoechst 33342 (ThermoFisher, cat. no. 62249) in 1x PBS, for 
15 min at 30 °C. 11 cm region of sections was scanned using Eclipse Ti inverted 
wide-field fluorescence microscope (Nikon, Japan) with 40X objective. Automatic 
nuclei segmentation was performed using Ilastik93 open-source pixel classifier 
software, by training the software on a single tissue scan. Cells were counted in 
five 1.71.5 mm regions of each tissue sections that overlap with tumor dense areas 
annotated in the same section by a certified pathologist.
2.2.6 BLISS and CUTseq adapters 
We purchased the oligonucleotides as standard desalted oligos from Integrated 
DNA Technologies (IDT). UMIs were generated by random incorporation of the 
four standard dNTPs using the ‘Machine mixing’ option. Oligos were diluted to 
10 μM and sense oligo phosphorylated for 1 h at 37 °C with T4 Polynucleotide 
Kinase (NEB, cat. no. M0201), after which an equimolar amount of anti-sense 
oligo was added. PCR thermocycler was used to anneal both oligos by incubating 
for 5 min at 95 °C, followed by gradual cooling down to 25 °C over a period of 
45 min (1.55 °C min−1).
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2.2.7 Sequencing and data pre-processing 
For BLISS and CUTseq:
The sequencing was performed on Illumina NextSeq 500 platform using NextSeq 
500/550 High Output Kit v2 chemistry for single-end (1x76) or paired-end (2x150) 
sequencing. Based on index sequences of pooled libraries, raw sequencing reads 
were demultiplexed by Illumina’s BaseSpace and FastQ files were generation. A 
custom-built pipeline was used to scan for the reads that contain the proper prefixes 
(i.e., 8nt UMI and 8nt sample barcode) with allowance of up to two mismatches in 
UMI and up to one mismatch in the barcode. Then the prefixes were clipped off 
and stored, reads were aligned to (GRCh37/hg19 for human, NCBI37/mm9 for 
mouse) reference genome with BWA-MEM (version 0.7.17-r1188)94. The reads 
with the mapping quality scores of ≥ 30 were kept, and a further filtering step 
based on UMI sequences to identify and remove PCR duplicates was applied by 
searching for proximal reads (at most 30 bp apart in the reference genome with at 
most two mismatches allowed in the UMI sequence). Eventually, for downstream 
analysis a BED file containing a list of genomic locations associated with a number 
of unique UMIs was generated. 
2.3 Summary of research papers 
2.3.1 BLISS is a method to profile natural and artificially 
induced DSBs
Given the importance of DSBs in pathological disorders and their role in revolu-
tionary genome-editing technologies such as CRISPR systems, precisely mapping 
the location and frequency of DSBs along the genome is of great interest for better 
understanding the biology of DSBs, genome instability and specificity of genome 
editing technologies. Although several technologies have been developed to map 
DSBs, each comes with some limitations as discussed in the introduction chapter. 
Therefore, to overcome the limitations related to existing technologies, in Paper I 
we developed a quantitative, genome-wide method termed Breaks Labeling in Situ 
and Sequencing (BLISS)95 [Fig. 10] to profile the genomic landscape of DSBs. In 
BLISS, cells or tissue sections are deposited onto a solid surface (e.g. coverslips 
or microscope slides) and fixed in 4% PFA, which allows the subsequent  reactions 
to be performed in situ, thus minimizing the introduction of artificial DNA breaks 
and sample loss. DSBs are blunted in situ using T4 DNA polymerase, and then 
a double-stranded DNA oligonucleotide adapter containing the T7 promoter 
sequence, followed by RA5 Illumina sequencing adapter, a short random stretch 
of 8–12 nucleotides that acts as unique molecular identifier (UMI), and finally 
a barcode sequence that enables sample multiplexing, is ligated to the blunted 
DSB ends. After DSB ligation, genomic DNA (gDNA) is extracted, sonicated to 
create fragments between 300-800 bp, and then the sequence juxtaposed to the 
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labeled DSB is linearly amplified by T7-mediated in vitro transcription (IVT). The 
RNA product of IVT is then used to prepare sequencing library to be loaded onto 
Illumina sequencing platforms. BLISS adapter design features some important 
advantages; linear amplification mediated by T7 approach reduces PCR amplifica-
tion biases as previously described96 and it makes the assay more sensitive as only 
tagged DSB sites are amplified; the UMI is used to filter out PCR duplicates97 and 
enables distinguishing and quantifying breaks occurring at the same nucleotide 
position in different alleles or cells; and the barcode is employed to label different 
samples for multiplexing and cost reduction. 
Figure 10. BLISS is an in situ method for detection of DSBs in fixed low-input materials. 
Cell or tissue samples are fixed on a solid surface and a double-stranded synthetic oligo 
linker (see legend) is ligated to blunted DSB ends. Tagged DSBs are linearly amplified 
by in vitro transcription using the T7 promoter sequence that is integrated in the BLISS 
linker. The second sequencing adapter is ligated and the sample is PCR amplified. Finally, 
a BLISS library is subjected to high-throughput sequencing.
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First, we demonstrated the versatility of BLISS in different sample types, from 
cell lines to tissue sections and nuclei suspension obtained from biopsies. Using 
BLISS, we were able to quantify and map endogenous and drug-induced DSBs 
(for example by DNA topoisomerase II inhibitor etoposide) in low-input samples. 
We measured endogenous DSBs in low input samples (approx. <5000) of three 
KBM7 cell replicates sequenced at saturation and demonstrated that BLISS was 
accurate and quantitative enough to be able to estimate 80–100 DSBs per cell, 
which was in line with the number of γH2A.X foci quantified by microscopy in 
the same cell line [Fig. 11 A-C]. The number of DSBs per cell was estimated by 
counting the number of unique reads – meaning a correct BLISS barcode, followed 
by a unique UMI, and a read that mapped to a unique genomic location – divided 
to the number of cells or genome-copies equivalent.  
Figure 11. (A) immunofluorescent staining of γH2A.X. Blue; DAPI, Red; γH2A.X signals. 
(B) Distribution of the number of γH2A.X foci per cells. n, number of cells analyzed. 
The number near the dashed red line equals the mean number of γH2A.X foci per cell. 
(C) Estimated number of DSBs per cell in three replicates of KBM7 cells sequenced at 
increasing sequencing depth. Dashed line, hyperbolic interpolation.
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To show the applicability of BLISS in primary cells and tissue, which would help 
investigation of DNA damage and repair processes in animal models and clinical 
samples, we profiled endogenous DSBs in mouse embryonic stem cells (mESCs) 
[Fig. 12 A-B], mouse liver biopsy [Fig. 12 C-D] and mouse tissue sections [Fig. 12 
E-F], which revealed strong enrichment of DSBs both in the neighborhood of 
transcription start sites (TSS) and along the gene body of highly expressed genes, 
which corroborates with previous findings80 that transcriptional-associated pro-
cesses can induce DSBs that in part govern gene regulation80,98,99. Furthermore, the 
top hit genes with highest enrichment of DSB levels in liver samples revealed to 
be involved in liver-specific metabolic processes found by Gene Ontology (GO) 
analysis, indicating that BLISS is capable of capturing endogenous DSBs related 
to tissue-specific processes along with its versatility. 
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Figure 12. (A) Percentage of sequenced DSB ends mapped ±4.5 kb around the TSS of the 
top 10% and bottom 10% expressed genes in two biological replicates of mouse embryonic 
stem cells. Dashed lines, spline interpolation. (B) Number of sequenced DSB ends mapped 
per kilobase inside the gene body of the top 10% and bottom 10% expressed genes in mouse 
embryonic stem cells. n, number of biological replicates. Whiskers, 2.5–97.5 percentile range. 
P, Mann-Whitney test. (C) Percentage of sequenced DSB ends mapped ±4.5 kb around the 
TSS of the top 10% and bottom 10% expressed genes in mouse liver nuclei. n, number of 
biological replicates. Dots, mean value. Whiskers, range. Dashed lines, spline interpola-
tion. (D) Number of sequenced DSB ends mapped per kilobase inside the gene body of the 
top 10% and bottom 10% expressed genes in mouse liver nuclei. n, number of biological 
replicates. Whiskers, 2.5–97.5 percentile range. P, Mann-Whitney test. (E) BLISS on mouse 
liver tissue section showing sequenced DSB ends of the top 10% (red) and  bottom 10% 
(blue) of expressed genes mapped in ±1 kb interval around the TSS. n, number of biological 
replicates. Dots, mean value. Whiskers, min-max range. Dashed lines, spline interpolation. 
(F) Number of sequenced DSB ends mapped per kilobase inside the gene body of the top 
10% and bottom 10% expressed genes in mouse liver tissue section. n, number of biologi-
cal replicates. Whiskers, 2.5–97.5 percentile range. P, Mann–Whitney test.
A B C 
D E F 
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Moreover, BLISS in U2OS cells treated with the topoisomerase II inhibitor etopo-
side enabled us to quantify the number of unique DSB ends in an increasing dose-
dependent manner similar to microscopy-based γH2A.X measurements [Fig. 13 
A-B]. We observed that upon etoposide treatment, DSBs are accumulated at recur-
rent genomic locations that are significantly enriched in the neighborhood of TSS 
[Fig. 13 C]. This finding was also in line with previous reports that etoposide has 
prominent effects around TSS – likely because of the role of topoisomerase II in 
relieving the torsional stress associated with replication/transcription fork pro-
gression and enhancer-promoter interactions29,100,101 – and further demonstrated 
the ability of BLISS to quantitatively measure DSBs in different sample types 
and conditions. 
Figure 13. (A) Nuclear intensity measurements of γH2A.X in untreated versus etoposide-
treated U2OS cells. n, number of analyzed cells. Whiskers extend from 2.5 to 97.5  percentiles. 
(B) Percentage of sequenced DSBs in control versus etoposide-treated U2OS cells. Two 
biological replicates were analyzed. For each condition, the same amount of genomic DNA 
was loaded into a single IVT reaction, and a single sequencing library was prepared for 
each replicate. (C) Fraction of DSB locations mapped around the transcription start sites 
(TSS) in control versus etoposide-treated U2OS cells as a function of the minimum  number 
of UMIs per DSB location. Dashed lines, linear interpolation. Color shades, 95%  confidence 
intervals.
A B C 
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To broaden the application of the BLISS method and assess its sensitivity at the 
same time, we next aimed to characterize the genome-wide on/off-target activities of 
two CRISPR-associated RNA-guided endonucleases, Cas9 and Cpf1 (Cas9-BLISS 
& Cpf1-BLISS), and also benchmark BLISS with other available gold standard 
CRISPR off-target screening methods, such as GUIDE-seq, Digenome-seq and 
BLESS (reviewed in introduction chapter). Cas9 and Cpf1 act as molecular  scissors 
and their cutting mechanisms generate site-specific blunt and staggered DSBs 
respectively. However, off-target cleavage activities of these CRISPR nucleases 
represents a major concern as they can lead to unwanted mutations and cancer 
risk102,103, and since these genome editing technologies are already used in several 
clinical trials, their specificity needs to be thoroughly assessed.
We developed a workflow as described in the method chapter to screen the  cleavage 
activities of aforementioned nucleases [Fig. 14 A]. We first started to characterize 
the specificity of Streptococcus pyogenes Cas9 (spCas9) and two sgRNAs targeting 
EMX1 and VEGFA genes that showed high off-target frequencies in the human 
genome and have already been assessed by all the other three available methods. In 
brief, Cas9-BLISS was able to identify on-target DSB sites as expected, along with 
discovering of many off-target sites that were successfully validated by  targeted 
next generation sequencing (NGS), including many sites previously identified by 
other methods [Fig. 14 B-D]. Although these comparisons showed that all  methods 
agree on the top identified off-target sites, they differ in the number of weaker 
off-target sites, especially in the VEGFA gene.
Eventually, we aimed to compare the DNA-targeting specificity of the recently 
described CRISPR-associated endonuclease Cpf138 with Cas9 using BLISS technol-
ogy. We evaluated Cpf1 from Acidaminococcus sp. (AsCpf1) and Lachnospiraceae 
bacterium (LbCpf1), and since the Cpf1 system recognizes a T-rich protospacer-
adjacent motif (PAM) 5′ of target sites, compared to the Cas9 system where a 3′ 
G-rich (NGG) PAM is utilized, we selected six Cpf1 targets across four different 
genes for off-target evaluation using BLISS and targeted NGS, by which four 
targets have NGG PAMs on the 3′-end to enable a dual targeting for simultane-
ous comparison between these CRISPR systems. Comparing BLISS results with 
guides used for AsCpf1, LbCpf1, SpCas9 and eSpCas9, we consistently found 
fewer bona fide off-target sites for the two Cpf1 orthologues, suggesting that 
indeed Cpf1 has a higher level of specificity than Cas9, and that is in line with 
other recent findings83 [Fig. 15]. 
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Figure 14. (A) BLISS workflow for CRISPR off-target detection. (B) Shows on and off 
 target sites identified by BLISS, BLESS, GUIDEseq and Digenome-seq. BLISS targets were 
ranked in descending order based on the number of unique DSBs aligned to the target per 
105 unique BLISS reads. Colored boxes in the three other benchmarked methods, BLESS, 
GUIDEseq and Digenome-seq columns indicate when the BLISS target was previously found 
by these methods. Each individual site was validated by targeted deep sequencing and the 
percentage of reads containing an insertion or deletion (indel) is shown. (n=3, error bars 
show s.e.m.). ON, means on-target. OT, off-target. (C) Overlaps between on and off-target 
sites identified by BLISS versus BLESS, GUIDEseq and Digenome-seq.
A 
B C 
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Figure 15. Comparison of BLISS results with guides used for AsCpf1, LbCpf1, SpCas9, 
and eSpCas9. Individual sites identified across two bio-replicates of BLISS were validated 
by targeted deep sequencing and the percentage of reads containing an insertion or deletion 
(indel) is shown. (n=3, error bars show S.E.M.). Dotted lines indicate the matching on 
target sequences for the different enzymes.
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We observed that, although all the four methods are generally in agreement on 
the top identified off-targets, they differ in the number of weaker off-target sites, 
which indicates that they all can be used as complementary/alternative tools based 
on their limitations. These results further demonstrated the specificity, sensitivity 
and broad applicability of BLISS. Altogether, we developed a quantitative and 
highly versatile method that can offer several unique features such as: 1) direct 
in situ DSBs labeling on solid surfaces to avoid introduction of artificial breaks, 
providing the applicability to low-input samples and tissue sections, as well as 
easy scalability by performing all in situ reactions and washes on a solid surface 
– if input sample is not limiting, the reactions can also be done in solution in-tube 
which provides additional versatility; 2) lack of dependency on repair pathways 
(e.g. NHEJ) for DSB labeling; 3) by employing UMI for quantification of DSBs 
and removing PCR duplicates the method is able to discriminate the DSB events 
that occur at the same genomic locations but in different alleles or cells; 4) the 
methods is multiplexable and cost-effective using barcodes before pooling samples; 
and 5); and provides a genome-wide quantitative view of DSB landscapes. We 
demonstrated that BLISS is a quantitative method to detect endogenous and drug-
induced DSBs, which is sensitive enough to assess the DNA-targeting specificity 
of CRISPR-associated RNA-guided DNA endonucleases. Therefore, we believe 
that BLISS is a powerful and versatile method for genome-wide DSB profiling 
to advance the study of endogenous and artificially induced DSBs in different 
sample types and conditions.
2.3.2 BLISS-generated DSBs data can be used to model 
genome fragility 
It is thought that improper repair of DSBs can lead to structural variations (SVs)104, 
and that each tumor contains a unique constellation of single nucleotide mutations 
and structural variants, of which only a tiny fraction of these mutations is cable 
of driving tumorigenesis105. Although there is evidence that SVs can drive the 
tumor progression, it has been difficult to determine among the many thousands 
of detected SVs, which ones might be advantageous for the tumor. 
In a collaborative project, we aimed to computationally build a set of DSBs  models 
to predict the frequency of expected breakage across the human genome. We 
speculated that cancer genomes harbor vulnerable regions (i.e., hotspots) where 
DSBs occur at higher frequency, while others have low frequency of genomic 
rearrangements (i.e., cold-spots) due to their essential integrity. One approach to 
find such hot and cold loci is to compare the genome-wide DSBs and observed 
rearrangement breakpoints frequencies in large tumor cohorts, such as TCGA (The 
Cancer Genome Atlas) and ICGC (International Cancer Genome Consortium). 
These public sources contain a collection of large structural variations from 
many patients and different cohorts. Since BLISS data were not available for the 
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samples in these repositories, we applied a machine learning approach – random 
forest – on four DSB datasets produced by different DSB mapping platforms that 
cover three cell lines; NHEK (keratinocyte cells, DSB data generated by BLESS 
and DSBCapture), K562 (erythroleukemia cells, DSB data generated by BLISS), 
MCF7 (breast cancer cells, DSB data generated by BLISS), and applied a random 
forest regression model to link DSB and SV profiles. 
We selected these cell types as they have been extensively profiled by the 
Encyclopedia of DNA Elements (ENCODE) for a variety of chromatin-binding 
factors and genomic features (i.e., open chromatin assayed by DNase-seq, POL2B 
binding, CTCF binding and five histone modifications assayed by ChIP-seq, rep-
lication timing assayed by Repli-seq, expression assayed by RNA-seq). We build 
the random forest regression models at 50 kb resolution in order to generate quan-
titative measures of the relative importance of a variety of these matched features 
to model DSB susceptibility [Fig. 16].
Figure 16. Genomic tracks at 50 kb resolution across a representative region of chromo-
some 1, which display similar patterns of DSB frequency profiles of NHEK cells (generated 
by DSBCapture and BLESS methods), K562 and MCF7 cells (generated by BLISS) and 
a variety of chromatin and sequence features. 
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Using DSB frequency models we found strong and significant correlations between 
predicted and observed DSB frequency in all of the four DSB datasets (Pearson’s 
coefficients 0.83-0.92) [Fig. 17 A]. In addition, we found that 11 selected genomic 
features suffice for the construction of highly predictive accuracy models. Our 
analysis revealed that the most influential feature in DSB frequency prediction is 
replication timing across all models [Fig. 17 B]. We observed that early replication 
correlates with high DSB regions, which was in line with previous report106. We 
also found that histone marks H3K36me3, usually associated with active genes 
was enriched at high DSB regions and H3K9me3, generally linked to gene-poor 
heterochromatin, at low DSB regions [Fig. 17 C], which was also in agreement 
with previous reports that, in cancer, SVs disproportionally accumulate within the 
early replicating, gene-rich portions of the genome, and are rather depleted in late 
replicating gene-poor regions 107–109. 
Figure 17. DSB frequency models generated from chromatin and sequence features. 
(A) Eleven genomic features at 50 kb resolution used for random forest regression model 
predictions and compared to DSB frequencies datasets of four cell lines. (B) Particular 
predictive features are ranked based on their importance for the models. (C) Heatmap show-
ing modeling accuracy and the polarity of genomic features, in which, columns are ordered 
by observed frequency of DSBs (top row) and features used to create the model ordered 
based on average variable importance shown in rows (the third to second to the last row). 
A 
B 
C 
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DNAse-seq experiments, which are used to identify regions of open chromatin, 
ranked as the second most important future across three models, and as the fourth 
in the MCF7 model. In addition, we found that RNA-seq is not a strong predictor 
for DSB susceptibility, despite the fact that DNAse-seq peaks are often enriched at 
the promoters of active genes. This observation suggests that information on open 
chromatin at transcriptionally active genes and associated regulatory factors (e.g., 
DNAseq, H3K4me4 and POL2B binding), instead of their transcription levels, is 
the main predictor of the frequency of DSBs.
The recurrent patterns of genomic features indicate that many factors have a similar 
effect on frequency of DSB in each of the investigated cell types, and therefore, a 
model trained in one cell type can generalize well to another cell type. For instance, 
a model trained in NHEK cells can be used to predict frequency of DSBs in K562 
cells with its associated genomic features as input. This approach enabled us to 
construct predictive DSB frequency profiles for cell lines that lack actual high-
resolution DSB data. In addition, we found a moderate correlation between the 
frequency of DSBs across cell types, which suggests that a considerable propor-
tion of DSB susceptibility of the genome is cell type-specific. 
Once we confirmed the accuracy of these models, we asked how the DSB  predic-
tions for the three cell types (as they are often used as models for cancer) that we 
have DSB maps for relate to the patterns of SV breakpoints observed in tumor 
sequencing studies of squamous cell carcinomas (relevant to NHEK cells), blood 
cancers (relevant to K562 cells), and breast tumors (relevant to MCF7 cells) in 
TCGA and ICGC public repositories. The data in these repositories were analyzed 
as pancancer datasets, gathering all cancer types together, but also as three cancer 
type subgroups. Similar to what we performed for DSB datasets, the number of 
tumor SV breakpoints was determined at 50 kb resolution (i.e., in a 50 kb bin, 
a single DSB was counted if either or both ends of a SV overlapped the region) 
for each of the TCGA and ICGC SV datasets. Overall, by looking at the ICGC 
data, we found low-correlations between the number of SV breakpoints and DSB 
predictions. However, when we restricted our analysis to enriched SV breakpoint 
(ESB) regions (i.e., 50 kb bins with SV breakpoint counts in the top 5% genome-
wide) we found increased correlation with the DSB model predictions [Fig. 18]. A 
significant increase in the correlation with DSB model predictions in NHEK and 
MCF7 was seen for pancancer, carcinoma, blood, and breast tumor enriched ESBs. 
In addition, in K562 DSB model predictions, significant increases were observed 
for all cancer subsets, except blood ESBs [Fig. 18 A-C]. Seeing the significant 
increase in DSB model predictions for carcinoma ESBs, indicates that in these 
cancer types, DSB susceptibility – as captured by predictive models – possibly 
shapes the landscape of SVs. However, from TCGA data, none of the subgroups 
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showed agreement, apart from the blood cancer ESBs, which might be due to 
low resolution of TCGA that makes it not very suitable for accurate detection of 
breakpoints. However, focusing on ICGC-annotated SV across all tumor types, 
overall, significant elevations for ESBs covering all SV classes except insertions 
were seen by our models [Fig. 18 D-F]. In relation to that, as insertions may occur 
through different mechanisms – for example by transposable element activity 
rather than by DNA damage and repair processes – they may be less influenced 
by DSB susceptibility. 
Figure 18. Violin plots illustrating regions enriched for cancer SV breakpoints (ESBs). 
(A-C) The top 5% SV breakpoint frequencies regions from ICGC database are shown with 
their predicted DSB values for three cell types (NHEK, K562, MCF7) that were used as 
models. Cohorts in ICGC are shown as pancancer and divided into three cancer categories: 
carcinoma, blood, and breast cancers. (D-F) The counts of SV breakpoints from ICGC 
separated by the type of SV, and regions with SV breakpoint  frequencies in the top 5% are 
shown with their predicted DSB values for three cell types. The  numbers after the labels 
in x-axis indicate cutoffs for SV breakpoint counts of the top 5% ESBs, and the numbers in 
parenthesis show how many 50 kb regions meet the cutoff. Significant higher values in DSB 
predictions for the ESBs relative to non-ESBs for each category are indicated by stars 
(Wilcox ranked sum test). 
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Next, we aimed to identify hot and cold spots for structural variant breakpoints in 
tumors. To this end, we developed a new metric, namely the d-score, to measure 
the difference between the SV breakpoints log p value in tumors and the pre-
dicted DSB log p value of a given DSB model in a 50 kb window of the genome. 
Then in the ICGC tumor cohort, we classified regions of interest based on the 
d-score metric as: i) regions with significantly more SV breakpoints than expected 
(CancHpredL; cancer high, predicted low or SV hotspots), ii) regions that have 
lower SV breakpoints than expected (CancLpredH cancer low, predicted high or 
SV coldspots), iii) regions that have both high SV breakpoint frequencies and high 
predicted DSB values (cancHpredH), which correspond to genomic regions with 
remarkably high frequencies of SV on the background of high susceptibility to 
DSB, and lastly iv) regions with high SV breakpoint frequencies but close to zero 
predicted DSB rates (cancHpredL2; in principle they are SV hotspots but we found 
that due to their association with low mappability, they are most likely repetitive, 
heterochromatic and artifact-enriched regions). We then used circular permuta-
tion test to assess the significance of a range of functional annotation enrichments 
(i.e., consisting of two putative cancer gene sets; 260 genes from the Cancer5000 
dataset, and 561 genes from the COSMIC database). In addition, a set of 15,415 
super enhancers, common fragile sites, and chromatin states from ENCODE were 
included in these four classes of regions. We found that, in cancHpredL class of 
hotspot regions significant enrichments in both gene sets were observed, although 
not in RefSeq genes, which suggests SVs may underlie the frequent alteration of 
these genes in cancer. In addition, it turned out that cancHpredL hot spot regions 
are significantly depleted for active chromatin regions (e.g., active promoters, 
enhancers and insulators), possibly due to the fact that these regions do not have 
low predicted DSB. In another class of regions, CancHpredH (high suscepti bility 
region) enrichment was observed for RefSeq genes, in both cancer gene sets, 
active promoters, strong enhancers, and insulators [Fig. 19]. Likewise, the cold-
spots CancLpredH class occupy gene-rich regions, active promoters and strong 
 enhancers regions, indicating that perhaps purifying selection controls the integrity 
of some genes and distal regulatory regions.  
We finally looked into functional annotation of regions of interest. We examined 
two classes of regions; the cancHpredL class (ten 50 kb regions with the highest 
d-scores) to uncover genes that might be re-assigned as oncogenic because of having 
higher SV breakpoints frequency than expected in cancer, and cancLpredH class 
(ten 50 kb regions with the lowest d-scores) that we predicted to be under purify-
ing selection, for signals of potential functionality. To perform this analysis, the 
NHEK cell DSB model predictions were paired with carcinoma SV  breakpoints 
from ICGC. We found that, in the regions with highest d-scores, nine out of ten 
examined regions overlapped with a gene, and four of them overlapped with 
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COSMIC genes; CHEK2, CDKNI2A (known tumor suppressors), TMPRSS2 and 
ERG (often involved in translocation and in the formation of fusion oncogenes). We 
also found that two adjacent 50 kb regions of chr17q12 overlapped GRB7, which 
its protein product interacts with a well-known proto-oncogen and IKZF3, which 
is involved in B lymphocyte regulation, differentiation and chromatin remodeling. 
In addition, a known fragile site, FRA17A, corresponds to this region as well. 
Regarding regions with the lowest d-score, seven out of ten overlapped with a 
known gene and two oncogenes. For example, the oncogene CDC27 is a highly 
conserved gene that interacts with mitotic check points proteins and is thought to 
be necessary for cell survival. We also found a non-coding RNA (LOC654342) in 
the centromeric region on chr2, which overlaps with H3K27ac, an active enhancer 
mark, that may be acting as a regulatory component. 
These findings show another aspect of BLISS technology as a genome-wide DSB 
mapping method that can be used to generate a comprehensive list of candidate hot 
and cold spots regions in different tumor types to further illuminate the  molecular 
basis of genome fragility, and possibly identify novel diagnostic markers or  targets 
for treatments. 
Figure 19. Regions were categorized into four classes based on d-score (a measure of the 
deviation of the observed breakpoint frequencies from the predicted or expected DSB fre-
quencies); high (cancHpredL) and low (cancLpredH), cancHpredH (regions with d-scores 
near zero), and cancHpredL2 (low mappability regions). Using circular per mutation, each 
category was tested for enrichment of various annotations. The yellow dotted line indicates 
significance (p < 0.01). Numbers in parentheses show how many 50 kb regions found in 
each category, out of 61,903 in total.
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2.3.3 CUTeq is a cost-effective method for DNA copy number 
alterations profiling
 Cancer is a complex and heterogeneous disease condition which is strongly asso-
ciated with genomic instability, such as copy number alterations (CNAs) – dupli-
cations and deletions of genomic sequence110,111. There are several mechanisms 
that underlie the generation of somatic CNAs, including cellular repair systems 
NAHR and NHEJ, which are activated by the presence of DSBs64. Conceptually, 
chromosomal instability like CNAs can promote the production of genetically 
distinct populations of cells, thus in case of cancer, they can increase intra-tumor 
heterogeneity (ITH) – i.e., subpopulations of cells within a single tumor can exhibit 
distinct genomic profiles – that may confer a selective growth advantage such as 
enhanced cell proliferation, metastatic behavior and chemotherapeutic drug resist-
ance to a certain subpopulation of cells112. Thus, the ability to accurately identify 
and evaluate CNAs and the causative genes are of great clinical interest, as they 
may represent valuable diagnostic and prognostic biomarkers with implications 
for cancer treatment decisions. Sometimes, CNAs, which may affect only a small 
number of cells, can be undetectable, especially if the molecular analysis is per-
formed on a larger mixed pool of normal and variant tumor cells113. Understanding 
the spatial complexity of ITH from a CNAs perspective requires the development 
of high-throughput methods that can preserve topographical information about 
the tissue context to capture and analyze multi-regions of a single tumor section. 
With this goal in mind we aimed to establish a method to construct highly multi-
plexed DNA libraries for reduced representation genome sequencing of multiple 
samples in parallel that also enables integrating microscopy and sequencing tools 
to explore spatial ITH of CNAs in primary tumors, metastases and as well as cell 
lines that we termed CUTseq. Since the focus of our lab was to develop methods 
to study genomic instability, during the course of BLISS development in paper I, 
we redesigned the BLISS protocol to exploit it for CNAs profiling in paper III. 
Basically, CUTseq is similar to BLISS, with the difference that DSBs are artifi-
cially induced by restriction digestion on purified genomic DNA prior to ligation 
in solution. 
Essentially, CUTseq just needs gDNA that is extracted from any types of samples, 
ranging from non-fixed, fixed cell lines or even FFPE tissue sections. For cell lines, 
gDNA can simply be extracted according to desired protocol, and in case of tissue 
sections, multiple small regions of a single tumor tissue section on a microscopy 
slide is marked with PinPoint DNA Isolation System (ZymoResearch), which acts 
as a glue on tissue and can then be peeled off using a small needle and placed into 
different tubes. Genomic DNA is isolated and subjected to in vitro digestion using 
either a 4-base cutter (NlaIII) or a 6-base cutter (HindIII) that were chosen among 
a list of commercially available restriction enzymes that generate staggered DSB 
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ends and are methylation-insensitive, followed by ligation of modified BLISS 
linker that is compatible with staggered ends. As linker contains sample barcode, 
each small region collected from a single tissue section can be tagged with different 
barcodes, which provides an advantage of pooling them together after ligation step 
and proceed with only single-pooled sample. The sample is then linearly amplified 
using the power of T7 promoter sequence that is incorporated to linker (similar to 
BLISS) and finally RNA product is used to generate sequencing library114 [Fig. 20]. 
Figure 20. The workflow of CUTseq for multiplexed library preparation. (1) Extracted and 
purified gDNA samples are loaded into a multi-well plate (this can be done either manually 
or with a robotic device) and digested with a restriction enzyme (RE) that generates sticky 
ends. (2) DNA cut sites are ligated to a double-stranded oligo adapter containing comple-
mentary sticky ends, a sample barcode (SB), a unique  molecular identifier (UMI), and the T7 
promoter (T7). (3) Labeled gDNA is amplified by in vitro transcription (IVT), (4) followed 
by reverse transcription, (5) amplified by PCR for incorporation of sequencing adapters 
and (6) eventually is sequenced. RA5, RA3, SP7 and SP9: Illumina’s sequencing adapters.
Multiplexing feature of CUTseq is greatly beneficial for instance in tumor multi-
region sequencing application. Currently, in this approach DNA is either extracted 
from multi regions of the same tumor mass or from multiple tumor sites of the 
patient, and for each region a single library that is differently indexed is generated 
and pooled together in a same sequencing run115. Tumor multi-region sequenc-
ing approach has been used to profile ITH and reconstruct tumor evolution in 
different cancer types115, however, one big limitation is the size of the examined 
regions, which must be large enough to extract sufficient amount of DNA for 
preparing single sequencing library per selected region, and therefore preventing 
 examining a larger number of small regions. In addition, constructing a single 
library for every examined region comes with a high cost, which limits the appli-
cability of tumor multi-region sequencing approach as routine cancer diagnos-
tics. Therefore, to overcome the aforementioned limitations, we took advantage 
of CUTseq features, including its multiplexity and versatility which enable us to 
construct multi plexed DNA libraries from different sample types for both genome 
and exome  sequencing to call for CNAs and single-nucleotide variants. First, we 
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demonstrated the reproduc ibility of CUTseq in five cancer cell lines for CNAs 
profiling at increasing resolutions ranging from 1 Mb up to 30 kb. In segmented 
CNA profiles at all resolutions we found high correlation between matched HindIII 
and NlaIII  samples [Fig. 21 A-B]. We also found that each cell lines showed a 
unique pattern of CNAs profiles at different genomic locations regardless of tested 
enzymes. To confirm CUTseq specificity, we aimed to detect a clinically relevant 
ERBB2/HER2  oncogene amplification on chromosome 17, which is reported in 
BT474 and SKBR3 cells, but not in MCF7 cells116,117. Indeed, we observed that 
CUTseq was able to reproducibly detect cell type-specific amplification of ERBB2/
HER2 locus, using both HindIII and NlaIII restriction enzymes [Fig. 21 C].
Figure 21. (A) Example of CNA profiles (shown at 100 kb resolution) obtained from BT474 
cells using either HindIII or NlaIII. p, Pearson’s correlation between the two profiles. 
(B) Correlations (Pearson’s p) between the CNA profiles (shown at 100 kb  resolution) of 
five different cancer cell lines gDNA digested with either HindIII (rows) or NlaIII (columns). 
(C) CNA profiles along chr17 (NlaIII, shown at 100 kb resolution) in two HER2-positive 
(SKBR3 and BT474) and one HER2-negative cell line (MCF7). The locus containing the 
ERBB2/HER2 gene is highlighted in red. The ideograms of Chr17 are shown at the  bottom 
(red: centromeric regions). In all the CNA profiles, grey dots show individual genomic 
windows, while black lines represent segmented genomic intervals after circular binary 
segmentation. The numbers below each box represent chromosomes from chr1 (leftmost) 
to chr22 (rightmost). In all the cases, TRN refers to the ID of Turin samples.
A B 
C 
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Next, we aimed to assess the reproducibly of CUTseq on gDNA retrieved from 
FFPE tumor specimens. We generated two CUTseq library replicates from five 
FFPE tumor samples, including two colon adenocarcinomas (COAD) and three 
melanomas (MELA). We found that CNA profiles between replicates are highly 
similar at different resolutions [Fig 22. A]. In relation to this, we observed that 
between corresponding replicates, the fraction of genome that was detected by 
CUTseq as either amplified or deleted was highly correlated [Fig 22. B] and also, 
we reproducibly found that the distribution of amplified/deleted regions became 
shorter in length as we increased the resolution [Fig 22. C].
Figure 22. (A) CNA profiles (NlaIII, 100 kb resolution) in five matched replicate (Rep) 
libraries generated from gDNA extracted from FFPE tumor samples. COAD, colon 
 adenocarcinoma. MELA, melanoma. p, Pearson’s correlation between matched repli cates. 
(B) Correlation between the fraction of the genome (shown at 100 kb resolution) either 
amplified or deleted in each of the replicates (Rep) shown in (A). Each dot indicates one 
pair of replicates. Dashed line: linear regression. (C) Distributions of the length of seg-
mented genomic intervals called as amplified (AMP) or deleted (DEL) in the Rep1 and 
Rep2 samples shown in (A), at different resolutions. In all the CNA profiles, grey dots show 
individual genomic windows, while black lines represent  segmented genomic intervals after 
circular binary segmentation. The numbers below each box  represent chromosomes from 
chr1 (leftmost) to chr22 (rightmost). In all the cases, TRN refers to the ID of Turin samples.
A 
In addition, it turned out that overall CNA profiles were reproducible even at 10 kb 
resolution when we zoomed-in on individual chromosomes and new features 
including focal amplifications, deletions and more resolved complex patterns of 
alterations that at lower resolution could not be appreciated were revealed [Fig. 23].
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Figure 23. Examples of CNA profiles of three selected chromosomes, at two  different reso-
lutions, for the TRN4 replicates shown in Fig. 22 A. Focal alterations that are detected 
only at 10 kb resolution, in both replicates are indicated by arrows. Red: centromeric 
region. In all the CNA profiles, grey dots show individual genomic windows, while black 
lines represent segmented genomic intervals after circular binary segmentation. In all the 
cases, TRN refers to the ID of Turin samples.
We then assessed the sensitivity of CUTseq at sub-nanogram gDNA input, which 
is not achievable for most of commercially available kits. We extracted gDNA 
from a single FFPE breast cancer (BRCA) tissue section and created a multiplexed 
library with decreasing amount of CUTseq barcoded gDNA input (ranging from 1, 
0.5, 0.25, 0.125 ng) into the same IVT reaction. In relation to this, different PCR 
cycles were also tested to exclude biases introduced by PCR cycles. We found 
that segmented CNA profiles at various resolutions and PCR cycles remained 
extremely stable with high correlation between each other, even for the 0.125 ng 
lowest gDNA input [Fig 24. A-B]. These findings demonstrated that CUTseq is 
a sensitive and reproducible method for robust CNAs profiling from picogram 
amount of gDNA extracted from FFPE specimens, at different resolutions. 
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Figure 24. (A) Genome-wide CNA profiles (NlaIII, shown at 100 kb resolution) obtained 
using 120 pg of gDNA extracted from one FFPE breast cancer (BRCA) sample and three 
different numbers of PCR cycles performed during the final steps of CUTseq library prepa-
ration. (B) Correlations (Pearson’s p) between all the genome-wide CNA profiles (shown 
at 100 kb resolution) obtained from different amounts of gDNA extracted from the sample 
shown in (A). In all the CNA profiles, grey dots show individual genomic windows, while 
black lines represent segmented genomic intervals after circular binary segmentation. The 
numbers below each box represent chromosomes from chr1 (leftmost) to chr22 (rightmost). 
In all the cases, TRN refers to the ID of Turin samples.
A B 
Next we aimed to show the compatibility of CUTseq for NGS DNA library prepa-
ration. We benchmarked CUTseq with NEBNext® Ultra™ II, which is used as a 
standard commercial DNA library preparation kit. For this comparison, we used 
10 FFPE-derived gDNA samples of four different tumor types, consisting of three 
breast adenocarcinomas (BRCA), three colon adenocarcinomas (COAD), two gas-
trointestinal stromal tumors (GIST), and two melanomas (MELA). We generated 
two libraries per samples, one made by CUTseq and the other using NEBNext® 
Ultra™ II. We found strong correlations between CUTseq and NEBNext CNA 
profiles independent of various resolutions [Fig. 25 A]. In line with this, we also 
found high correlation between matched samples in fraction of the genome that 
was detected as either amplified or deleted [Fig. 25 B]. These findings further 
demonstrated the ability of CUTseq as a sensitive and reliable method for CNA 
profiling in FFPE samples. 
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Figure 25. (A) Genome-wide CNA profiles (NlaIII, shown at 100 kb resolution) obtained 
by CUTseq and NEBNext using gDNA extracted from ten different FPPE tumor  sample. 
BRCA, breast cancer. COAD, colon adenocarcinoma. GIST, gastrointestinal  stromal tumor. 
MELA, melanoma. p, Pearson’s correlation between matched CUTseq and NEBNext CNA 
profiles. (B) Correlation between the fraction of the genome (100 kb resolution) either 
amplified or deleted in each of the paired CUTseq and NEBNext samples shown in (A). 
Each dot represents one pair of replicates. Dashed line: linear regression. In all the CNA 
profiles, grey dots show individual genomic windows, while black lines represent segmented 
genomic intervals after circular binary segmentation. The numbers below each box repre-
sent chromosomes from chr1 (leftmost) to chr22 (rightmost). In all the cases, TRN refers 
to the ID of Turin samples.
A 
B 
We next aimed to assess the compatibility of CUTseq libraries for exome cap-
ture. We generated two replicates CUTseq libraries from gDNA of SKBR3 cells 
and performed exome capture using SureSelect kit from Agilent Technologies. 
As a control, two libraries using the same gDNA as input were used to generate 
two replicates libraries by a commercial kit from Agilent, which then were used 
for exome capture by SureSelect kit. Single-nucleotide variants (SNVs) calling 
of CUTseq and Agilent Technology revealed that genomic distribution and type 
of high-confidence SNVs were very similar between replicates of both methods 
[Fig. 26 A]. In both replicates of CUTseq, 72.3% of all the high-confidence SNVs 
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identified were detected [Fig. 26 B], while between the two methods 37.8% of all 
the SNVs were shared [Fig. 26 B], with CUTseq showing lower mean coverage 
per SNV, due to its nature as a reduced representation sequencing method [Fig. 26 
C]. In relation to this, we also obtained similar results using two different FFPE-
derived gDNA tumor samples [Fig. 26 D]. These results all together demonstrated 
that CUTseq libraries are compatible with standard exome capture and therefore 
can be used as a method for reduced representation exome sequencing.
A B 
C D 
Figure 26. (A, left) Shows all the SNVs called in two replicate (Rep) exome capture experi-
ments from SKBR3 cells-extracted gDNA and using either CUTseq or a  commercial kit for 
preparation of the library (Agilent), in multiple different annotated genomic regions that are 
partitioned. The legends, up- and downstream indicate 5 kb windows before and after the 
start of protein-coding genes, respectively. (A, right) Same as in (left plot), but different 
substitution types are shown. (B, top) High-confidence SNVs (at least 50 × coverage) over-
laps that called in the two CUTseq replicates shown in (A). (B, bottom) Overlap between 
all the high-confidence SNVs identified by CUTseq vs. Agilent, after merging matched 
replicates shown in (A). The percentages indicate the total number of SNVs in the union 
of the two sets. (C) Exome coverage for the same libraries shown in (A). (D) Same as in 
(c), but represents the libraries prepared from two distinct FFPE breast adenocarcinoma 
(BRCA) samples.
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To assess the versatility and high multiplexity of CUTseq, we developed a semi-
automated workflow based on contactless liquid-dispensing robot, which allows 
working with nanoliter reaction volumes and enables preparation of ready to 
sequence libraries in about 8 hours [Fig. 27 A]. As a proof-of-principle, 5 ng gDNA 
of HeLa cells were dispensed in each wells of 96-well plate, digested, differen-
tially ligated to 96 different CUTseq barcodes and then pooled together into one 
single tube for IVT reaction and library preparation. The library was sequenced 
shallowly yielding 88 out of 96 replicates (91.7%) with at least 100K usable reads 
[Fig. 27 B]. We also notice that the sequencing error rate was very low (median: 
1.62%; interquartile range: 1.58%–1.68%), indicating that even with quick diges-
tion and ligation in nanoliter volume, CUTseq is very precise [Fig. 27 C]. CNAs 
analysis of all the 88 replicates with at least 100K usable reads showed highly 
similar profiles with strong correlation between each other [Fig. 27 D]. In addi-
tion, genome fraction that was either amplified or deleted was uniform across 
replicates [Fig. 27 E]. These results indicated that CUTseq is highly multiplexed 
and cost-effective – total cost is considerably low for preparation of libraries for 
large number of samples compared to commercial kits – for preparing libraries 
of large number of samples, in addition to its precision, reproducibility and short 
turnaround time. 
Lastly, since one of the CUTseq feature is its applicability in multi-region tumor 
sequencing, we set to assess intratumor heterogeneity of CNAs and aimed to 
profile 35 archival FFPE samples from 14 patients (age of specimens: 9–27 yrs), 
consisting of primary tumors and one or more matched metastases previously 
profiled by whole exome sequencing. Each tumor sections were first stained with 
hematoxylin-eosin for imaging and morphological assessment before extracting 
gDNA from a large region (labeled as L with the size of ~7 mm2) that was con-
firmed by a trained pathologist to contain tumor cells [Fig. 28 A]. Each L region 
gDNA was split into half and labeled as L1 and L2 as technical replicates. In two 
cases we also extracted gDNA from several smaller regions  – labeled as S with 
the size of ~3 mm2 [Fig. 28 A]. In addition, remaining material after collecting L 
and S regions where used to extract gDNA from the full tissue sections (labeled 
as F) [Fig. 28 A]. In total, 133 different regions were retrieved, gDNA collected 
from each region was separately barcoded, pooled into four libraries (i.e., L1, L2, 
S and F samples) and sequenced enough to obtain at least 200K reads per region to 
generate CNAs profiles of 100 kb resolution. CUTseq revealed that CNAs profiles 
of matched L1 and L2 replicates are very similar and aneuploid genome fractions 
showed high correlation (Pearson’s p 0.98) [Fig. 28 B-C]. In addition, hierarchical 
clustering revealed that CNAs profiles of matched L1 and L2 replicates always 
cluster together from different samples and patients [Fig. 28 D], further indicating 
applicability and reproducibility of CUTseq in different sample types and formats. 
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Figure 27. (A) Low-volume non-contact dispensing device, I-DOT One MC, that was used 
in this study, and timeline for high-throughput CUTseq library preparation are depicted. IVT, 
in vitro transcription. The total workflow for a single person to prepare 1–2  libraries takes 
~8 hours, each containing up to 96 samples. The step for  dispensing samples can be either 
performed manually or using a liquid handling device such as I-DOT One. (B) Number of 
usable reads (after alignment and PCR duplicates removal) per sample (in this example 
5 ng gDNA extracted from HeLa cells) in one multiplexed CUTseq library prepared from 
96 replicate samples (n) , using I-DOT One. (C) The sequencing error rates distribution in 
the 96 replicates (n) shown in (b). (D) Genome-wide CNA profiles (shown at 1Mb resolu-
tion, averaged at arm level for visualization) for 88 replicates shown in (b) that yielded at 
least 300K usable reads. The  remaining 8 samples were not included since the number of 
usable reads was insufficient to  perform reliable CNAs calling. (E) Fractions of the genome 
either amplified (AMP) or deleted (AMP) in the 88 replicates (n) shown in (D). Each dot 
represents one sample. Error bars indicate the median and interquartile range. 
50
Figure 28. Multi-region DNA copy number profiling in FFPE breast cancer  tissue 
 sections. (A) Schematic representation of the tumor-rich regions, within individual FFPE 
breast cancer tissue sections, from which gDNA was extracted. S, small regions of ~3 mm2. L, 
large regions of ~7 mm2. For each L region, the extracted gDNA was split in two technical 
replicates, L1 and L2. F, all remaining tissue in the section. To capture the tissue from each 
region the PinPoint Slide DNA Isolation System™ was used. (B) Low-resolution (10X 
magnification) images of 35 tissue sections from primary (T) and metastatic (M) breast 
cancers from 14 different patients (note that not all the images shown here), stained with 
hematoxylin-eosin, and corresponding genome-wide CNA profiles, at 100 kb resolution, for 
F, L, and S (only for KI patients no. 13 and 14) regions. Black circles show the position, in 
each section, corresponding to the L region from which L1 and L2 replicates were obtained. 
Black arrowheads represent amplification of chr14q24 encompassing the RAD51B gene 
in patient KI2, and of chr17q12 encompassing the HER2 gene patient KI7. In all the CNA 
profiles, chr1 is on the left and chr22 on the right. (C) Pearson’s  correlation (ρ) between 
the aneuploid genome fractions across all L1-L2 replicates shown in (B). (D) Hierarchical 
clustering of the CNA profiles of all the F, L, and R regions, for KI patient no. 13 and 
KI patient no. 14. (E) Fractions of the genome either amplified or deleted in the regions 
with at least 2% of the genome either amplified or deleted (n), separately for primary (T) 
and metastatic (M) lesions. Each dot shows one region (n). Error bars represent the median 
and interquartile range. P, Mann-Whitney test, two-tailed.
A B C 
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Although we found that L regions typically cluster together with corresponding F 
regions, notably we observed that in patient KI-2 metastasis-b sample [Fig. 28 B, 
black arrowhead] of L region there is a ~900 kb amplification on chr14q24, 
encompassing the RAD51B gene, which was undetected in full section (F). 
Furthermore, two S regions of primary tumor from patient KI-14 showed numer-
ous CNAs profiles than other S, L and F regions [Fig. 28 B and D]. Moreover, 
from CNAs profiles and hierarchical clustering trees we observed that metastatic 
regions of the same tumor typically clustered together and apart from the regions 
of the corresponding primary lesion. Metastatic regions also showed a significantly 
higher load of amplifications and deletions compared to corresponding primary 
tumor regions (P-value = 0.006, Mann-Whitney test, two-tailed) [Fig. 28 D-E, note 
that not all the data shown here]. These results are in line with recent finding that 
breast cancer distant metastases show a different mutational landscape, although 
phylogenetically related, in comparison to primary tumor, due to accumulation of 
genomic instability and evolution of tumor118.  
These findings highlighted the power of CUTseq for high resolution multi-region 
sequencing to detect sub-clonal CNAs which can be undetectable when working 
with gDNA samples retrieved from larger tissue samples. 
Eventually, to find out how many of cancer genes are affected by CUTseq detected 
CNAs in different tumor regions, we explored the COSMIC119 database for 712 
cancer-associated reported genes, and we found that 241 genes (33.8%) were 
amplified, and 261 genes (36.6%) were deleted in one or more tumor sites, regions, 
or patients in our cohort. The top-three genes that found to be amplified were 
MYC, NDRG1, RAD21, while three-most frequently deleted genes were KMTA, 
PAFAH1B2, POU2AF1 [Fig. 29 A]. In addition, performing hierarchical cluster-
ing analysis showed that there are at least two major groups; the first one that 
includes both amplifications and deletions in a large subset of COSMIC genes, 
and another group harboring predominantly amplifications in a smaller subset of 
genes, including MYC, ERBB2, CCND1, MDM2, PIK3CA [Fig. 29 B] that are 
reported to be recurrently affected by CNAs in breast cancers120. 
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Among frequently amplified genes, 7 out of 14 patients (50%) had MYC and 9 
out of 14 patients (64%) had ERBB2 amplifications, whereas, 4 out of 14 patients 
(28.6%) showed deletion of classical tumor-suppressor TP53 gene among the 
 frequently deleted genes. Furthermore, CUTseq was able to detect HER2 ampli-
fication in patient primary tumor samples that were also annotated as HER2-
postive by immunohistochemistry (KI-2, 4, 9, 10, 11, 12 samples). Overall, our 
results demonstrated that CUTseq is a robust, versatile and sensitive method that 
is applicable in low-input materials from different sample types ranging from cell 
lines to clinically relevant tumor specimens to investigate CNAs at high spatial 
resolution and gain further insights into intratumor heterogeneity. 
2.4 Discussion and conclusions
This thesis reports the development of two novel genome-wide methods: BLISS 
for in situ profiling the genomic landscape of DSBs (in Paper I), and its applica-
tion to model genome fragility (Paper II); and CUTseq for profiling DNA copy 
number alterations (Paper III). 
Figure 29. (A, top plot) Shows the ranking of the 712 cancer-associated genes in COSMIC 
based on the number of samples (133 samples shown in Fig. 28 B), in which they were 
found amplified (AMP). The gene names shown on the plot refer to a subset of 31 COSMIC 
genes that were identified to be frequently amplified or deleted in 560 breast cancers. 
(A,  bottom plot) Same as (A, top plot), but for genes deleted (DEL) in the samples (133 
samples shown in Fig. 28 B). (B) Hierarchical clustering of the 712 COSMIC genes (rows) 
based on their amplification (red) or deletion (blue) status in each of the 133 samples shown 
in (Fig. 28 B) (columns). Gene names on the right represent 14 out of 31 genes that were 
previously identified to be either amplified or deleted in breast cancer. For each gene, the 
rectangles on the right indicate whether it is amplified (no boundary) or deleted (black 
boundary) in at least one sample (F, L, R) in the KI patient depicted with the same color 
in the first row above. In all cases shown in the figure, KI refers to the ID of samples from 
Karolinska Institute.
A B 
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2.4.1 BLISS maps the landscape of DSBs 
DSBs play crucial roles in the fundamental physiological processes of the cell 
(e.g., DNA replication and transcription). However, when not properly repaired, 
these represent one of the most dangerous types of DNA lesions, and are primary 
source of chromosomal rearrangements such as CNAs, which are closely related 
with genomic instability – a hallmark of cancers91,92. Dangerous as they are, site-
specific DSBs can also be deliberately introduced by programmable nucleases for 
genome-editing purposes33. Therefore, over the past few years there has been a 
significant interest in determining the DSBs genomic locations and frequencies. 
Presently, there exist a number of genome-wide technologies that can be applied 
to investigate various aspects of DSBs, ranging from studying the dynamics of 
DSBs in DNA damage, to measuring the off-target activity of genome-editing 
nucleases. For example, as described in the introduction chapter, several genome-
wide methods such as GUIDE-seq88, HTGTS89,86 and BLESS76 have been developed 
for DSB mapping and also specificity evaluation of CRISPR-Cas systems, each 
with its own strengths and weaknesses. To overcome some of the limitations of 
these technologies (described further in the introduction chapter), we introduced 
a novel method into the DSB-mapping technology toolbox. In Paper I we pre-
sented BLISS, as a versatile, sensitive and quantitative method for direct genome-
wide detection of endogenous and induced-DSBs in low-input sample of cells 
and tissue specimens. At the time this thesis was written, there were a handful of 
genome-wide DSB mapping methods available, which indicates the importance 
of accurately identifying these lesions and also reflects how complex and diverse 
is the field of DSB identification. 
With the currently available DSB mapping technologies that reveal different aspects 
of DSBs, assay choice can be based on specific research question and the types of 
samples. Those methods based on capture of DSBs through repair pathways, such 
as GUIDEseq88, IDLV87 and HTGTS90 reported to have high sensitivity, but their 
applicability beyond model cell lines is limited because: i) transfection procedure 
may induce cellular stress response, which can be a source of DSBs formation; 
ii) applicability of these methods are challenging in transfection-sensitive cells 
and in vivo settings ; iii) in the case of GUIDEseq for CRISPR off-target detection 
purpose, if off-target cleavage is detrimental for the cell (e.g., if the exogenously-
transfected DNA insert in an essential gene), it would cause the off-target to be 
masked due to underrepresentation within the population of cells; iv) in addi-
tion, studying endogenous DSBs related to replication and transcription may 
be challenging due to the need for transfection and the time-range required for 
the introduction of exogenous DNA – for example, when repair and accuracy of 
endogenous DSBs are high, those repair-dependent DSB tagging methods may 
miss a substantial amount of DSB events. 
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Despite the fact that in vitro DSB tagging technologies such as BLISS, DSBCapture 
and BLESS are more versatile, less disruptive, and do not rely on repair pathways 
due to labeling DSBs after fixation they do however have some limitations as well; 
for example, they provide only a snapshot of the DSBs that were not repaired at 
the time of fixation and therefore these methods do not reveal past breakage. In 
addition, their sensitivity can be affected by chromatin accessibility for blunting 
DSB ends and adapter ligation. 
One of these in vitro methods, Digenome-seq83, tried to overcome the chromatin 
accessibility problem by purifying the genomic DNA, digesting it with a high-
concentration of the nuclease of interest, and subsequently performing whole-
genome sequencing. Apart from the fact that this technique can only be used for 
nuclease off-target detection and not for endogenous DSB mapping (as the input 
material is purified gDNA), the problem with such a technology is that without 
any enrichment strategy of the cleaved sites, many sequencing reads derived from 
unmodified genome are wasted, which results in limited read depth and  sensitivity. 
In relation to this, another subsequent method, CIRCLE-seq was developed to 
overcome lacking enrichment for cleavage sites in Digenome-seq and eliminate 
the high background of random reads. This method is based on random shearing 
of gDNA and creation of intramolecular circularization, followed by removal of 
uncircularized (linear) DNA before in vitro Cas9 cleavage. This strategy reported to 
have higher sensitivity for off-target detection over Digenome-seq. However, this 
in vitro assay also misses the impacts of chromatin accessibility or other  cellular 
factors on cleavage activity. In addition, it requires a large amount of gDNA for 
circularization (~25 µg), which based on the availability of cellular source of 
gDNA can be a limiting factor. 
It must be noted that, all of the available DSB profiling technologies are population-
based assays, which typically require a high amount of starting material (e.g., a 
few million cells), and therefore they mostly capture mostly the loci with recurrent 
DSBs and miss the low-abundance events, which end up as background. However, 
so far only the BLISS method has proven to be applicable in low-input samples, 
and is the first method that introduced the quantitative DSB mapping using UMI. 
In line with this, BLISS implementation for single-cell DSB profiling can shed 
light on cell-to-cell variation and provides a better understanding of the hetero-
geneity of genome fragility in cells (particularly cancer cells) and repair outcomes, 
albeit, its feasibility and data analysis remain to be explored. 
Admittedly, BLISS technology has also its own limitations. Firstly, if the aim is to 
investigate rare DSB or translocation events, having only few thousands of cells 
may not be enough to capture those rare events, however, in follow up studies69,121 
we showed that BLISS can also be applied in cell suspension format in millions of 
cells, in order to not to be limited with only low-input samples. Secondly, quantita-
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tive application of BLISS using UMI may be challenging and complicated, since 
the total number of UMIs in the sample must be counted in order to estimate the 
total number of breaks. This is especially challenging when working with new 
samples, a large number of cells and also samples with abundant DSBs, and as 
such, one might be required to perform a series of sequencing at increasing depth 
(which is costly) in order to estimate the true number of DSBs in the sample. 
However, to solve this problem, a few approaches can be considered: i) a cheap 
and reliable solution we proposed was to use mathematical modelling methods, 
which can be used to determine the complexity of sequencing libraries based on 
data from very shallow sequencing runs. This approach can be helpful understand 
how deeply one should sequence, or predict how beneficial additional sequencing 
can be122. Another solution, could be the integration of a newly developed method 
for DSB quantification (qDSBseq)82, which claims to bring an accurate quanti-
fication power to any sequencing-based DSB labelling method with BLISS. Its 
strategy is based on introducing spike-in DSBs by low-frequency cutting restric-
tion enzymes and use them to for the calibration of BLISS data, which ultimately 
enables calculation of absolute DSB frequencies per cell. However, a side-by-side 
comparison with BLISS remains to be performed in order to see if it truly improves 
the quantification power. Thirdly, the application of BLISS in FFPE tissue samples 
can be challenging, since fixation and long tissue storage procedures often cause 
nucleic acid degradation and fragmentation of the DNA, which may result in the 
induction of artificial DSBs123. 
In terms of off-targets of CRISPR-Cas nucleases there are important aspects to 
consider, especially when moving into gene editing in human: i) despite the fact 
that genome-editing technologies are increasingly becoming more specific with 
lower-off target rates (e.g., by engineering and development of high-fidelity versions 
of Cas systems, such as eSpCas9124 and SpCas9-HF1125 together with discovery 
of CRISPR systems with naturally higher specificity feature such as Cas12a)126, 
the question is whether the development of increasingly sensitive assays is also 
needed to detect the very rare off-target events. In line with this, fundamentally, 
achieving ever-greater sensitivity for off-target detection is limited by the  number 
of input cells used in DSB detection assays. In relation to this, for instance, an 
off-target event with occurrence probability of one in million is likely missed 
when we analyze less than 500,000 patient cells edited in a culture dish ex vivo, 
because this off-target break may not occur in such a small number of cells. On 
the contrary, it is more likely to occur when we analyze one billion cells in an in 
vivo setting. Thus, it is important to note that although available technologies for 
off-target detection (e.g., in silico, in vitro/in vivo) can identify high risk loci, it 
will still be crucial to keep in mind certain aspects such as number of cells ana-
lyzed in order to extrapolate in vitro results to in vivo; ii) as the human genetic 
variation can alter the landscape of off-target, it can also create unique specific 
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off-target sites, and since detecting rare off-targets with possible negative out-
come is of our interest, in ideal scenario, all gene-therapy recipients should have 
their complete genome sequenced for in silico off-target prediction, in addition 
to having enough collected genomic DNA for personalized in vitro reaction; iii) a 
recent report showed that off-targets are not the only issue of concern in genome-
editing, in fact, unintended on-target changes such as large chromosomal dele-
tions, insertions and inversions that extend over many kilobases is another new 
dilemma127.  Such unintended chromosomal rearrangements by which crucial genes 
might end up being altered can potentially lead to serious health consequences. 
Importantly, these rearrangements might remain undetected because for the on/
off-target analysis usually a short-read NGS technology, such as Illumina is used 
for genotyping CRISPR/Cas-induced mutations. Therefore, long-read sequencing 
(such as PacBio) and long-range PCR genotyping can be applied to detect these 
unintended rearrangements127. 
Overall, it is indeed difficult to choose the best assay to capture most of either 
endogenous or induced-DSBs, however, when resources permit, the ideal strategy 
would be to combine repair-dependent DSB capture methods (e.g., IDLV, HTGTS, 
GUIDE-seq) and in vitro assays (e.g., BLISS, DSBCapture, BLESS) to generate 
a complementary picture of DSB events at a certain time point and also over a 
period of time. However, if the samples to be DSB-profiled are from clinical and 
precious origins, generally the cell numbers are limited and transfection is not 
feasible, and therefore in vitro based assays compatible with low-input material, 
such as BLISS, are favorable.
Extended applications of BLISS technology
With the help of available genome-wide DSB mapping technologies we have now 
gained further insights into the distribution of DSBs along the genome. One of the 
observations that has been revealed thus far is that transcriptionally active loci and 
TSS are particularly prone to break. Using BLISS technology, investigating the 
intricate relationship of DSBs formation, transcription, and chromosome architec-
ture has now been further substantiated by several follow-up studies.
For example, using BLISS, Iannelli et al.128 intersected DSB maps that were 
generated in the U2OS-AsiSI system with multi-layered expression profiling 
(RNA-seq, Bru-seq, CAGE, RNA POLII ChIP-seq), which enabled them to 
monitor transcriptions in regions where AsiSI cut sites were present. This study 
revealed that transcription was inhibited around AsiSI-induced DSBs, but not in 
uncut regions, in an ATM-dependent manner, and that transcriptional repression 
is progressively weakened by moving away from the vicinity of DSB sites128. This 
transcription repression phenomenon has been attributed to several mechanisms, 
such as degradation of RNA POL II, condensation of chromatin and recruitment 
of transcription repressor factor PRC1129–131.
57
Recently, Dellino et al.132 have also applied BLISS to investigate how transcription 
processes induce DSBs at discrete genomic loci in normal, unperturbed human 
mammary cells, and address how DSBs are processed and whether they are linked 
to cancer-associated translocations. They reported that DSBs are accumulated at 
promoters, 5′ splice sites and active enhancers upon the release of paused RNA 
POL II. In the absence of canonical DDR, these DSBs are processed by end-
joining, and POL II pausing at long genes seemed to be the main predictor and 
determinant of DSBs. 
In another study using BLISS, Gothe et al.133, studied the interplay between transcrip-
tional activity and the occurrence of MLL (Mixed lineage leukemia) chromosome 
translocations. They reported that TOP2-mediated DSBs were enriched in chroma-
tin loop anchors and associated with a high level of transcription. They observed 
that transcription is a major contributor of TOP2-associated DSBs, by showing 
that etoposide-induced DSBs were highly enriched in active genomic regions and 
POL II- occupied sites. In addition, these DSBs were positively associated with 
the level of transcription output at promoters and intragenic sites. Furthermore, 
occurrence of TOP2-induced DSBs substantially decreased in promoters and gene 
bodies upon inhibition of transcription elongation. They also reported that MLL and 
its fusion partners are highly transcribed, enriched at chromatin loop boundaries, 
and accumulate TOP2-induced DSBs in a transcription-dependent manner. Thus, 
the authores proposed that since TOP2-induced DSBs overlap with MLL and its 
fusion partners, they possibly drive the formation of oncogenic MLL transloca-
tions. Overall, the authors described that interplay between spatial 3D chromo-
some organization and transcription are major contributors of DSBs at recurrent 
genomic regions that frequently translocate in cancer.
Recently, in Paper II, we also showed that using BLISS-generated data from cell 
lines, one can construct computational models of DSBs to predict the frequency of 
expected breakages across the human genome69. By using random forest regression 
models from four DSB datasets, we generated quantitative measures of the relative 
importance of a variety of epigenetic marks, transcription factor occupancy, gene 
expression and other features related to DSB susceptibility. Our analysis revealed 
that the most influential feature in DSB frequency prediction is replication timing 
across all models. We also demonstrated that comparison of DSB profiles used 
for the creation of genome fragility models from cell lines with the landscape of 
rearrangement breakpoints in large tumor cohorts, such as TCGA and ICGC data-
bases, can be utilized to generate a comprehensive list of candidate hot and cold 
spots fragile loci in different tumor types.
In addition to the studies above, BLISS can also be exploited to unveil new layers 
of neural regulation and to characterize the molecular basis and functional conse-
quences of the emerging role of so-called activity-induced DSBs98. Occurrence of 
DSBs are particularly deleterious in neurons, since their damage repair capacity is 
58
reduced134 and as such, accumulation of DSBs might result in cellular senescence 
or apoptosis of post-mitotic neurons134, which in turn could account for various 
neuropathological and age-associated neurodegenerative disorders (for example in 
Alzheimer’s disease mouse model and human brain samples, elevated DNA breaks 
have been identified)135. Interestingly, recent findings demonstrated that neuronal 
activity specifically induces targeted DSBs involved in transcriptional regulation 
of a subset of neuronal early response genes (such as Fos, FosB and Npas4), which 
is mediated by TOP IIb98. In addition, it has been shown that the 3D genome is 
heavily rearranged during stem cells differentiation to favor the transcriptional 
and epigenetic changes that accompany differentiation136. Therefore, using BLISS 
technology combined with RNA-seq and chromosome conformation capture based 
methods (e.g., Hi-C) we currently aimed to profile the neural genomic landscape 
of DSBs and investigate its link to chromatin organization and transcriptional 
output during neural differentiation, by taking advantage of neuroepithelial-like 
stem cells derived from induced pluripotent stem cells 137. 
In view of the above, the successful integration of data generated from this model 
system might yield insights into temporal dynamics of DSB formation that affect 
transcription, chromosome architecture and organization in the nuclear space. In 
addition, we anticipate that this approach could potentially result in discovery of 
candidate fragile genes which are suspected to be integral in neurodevelopmental 
and neurodegenerative disorders. Repeated exposure of these candidate genes to 
transcription-dependent DSBs as a result of TOP II-activity may result in accumula-
tion of mutations in their regulatory regions, such as promoters. This phenomenon 
in turn could drive gene expression changes in gene regulatory networks associ-
ated with neurological disorders. In order to determine whether fragile promoter 
regions accumulate mutations, we aim to perform targeted promoter sequencing 
by  making capture probes following our recent iFISH pipeline138. We envision that 
this project could contribute to discover new layers of neural regulation, bringing us 
closer to understanding the molecular basis of complex neuronal-related diseases.
Another area that a modified-version of BLISS can be applied is for direct  detection 
and visualization of DSBs in single-cell. Currently, a common way for quantita-
tive measurement of DNA damage level and DSBs in single cell is by immuno-
fluorescence against activated DNA repair proteins (e.g., γH2AX and 53BP1), which 
are detectable as nuclear foci. However, this approach is an indirect measure ment 
of DSB, and also repair proteins may be detected even in the absence of actual 
DNA damage139,140. Alternatively, TUNEL (terminal deoxynucleotidyl transferase 
dUTP nick end labeling)141 and COMET142 assays have been used for DNA  damage 
detection. TUNEL enables exposed DNA ends labeling with the addition of deoxy-
nucleotides (either directly with a fluorescent label or with a chemical label) to the 
3’-hydroxyl terminus of DNA breaks, using the enzyme terminal deoxy nucleotide 
transferase141. In COMET assay, a suspension of single cells is embedded in an 
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agarose gel and spread onto a microscope slide. Cells are lysed and under alkaline/
neutral conditions the DNA unwinding and electrophoresis result in the migration 
of broken DNA fragments away from the nucleus, appearing like a ‘comet’. The 
extent of DNA damage can be determined based on the size, shape and distribution 
of DNA within the comet142. However, both methods are prone to artifact and have 
low-sensitivity, and as such are usually used for detecting massive DNA damages, 
such as apoptosis. Instead, we propose to design a Y shape-like BLISS adapter 
(termed Y-BLISS), through which, after in situ ligation to DSB ends, the flaps 
of adapter can be used to hybridize several fluorescently labeled detection oligos 
– similar to single molecule RNA FISH hybridization strategy. Alternatively, we 
can use our recent FISH based method (RollFISH)143 strategy, which exploits the 
padlock probe on the flab region of the adapter, followed by rolling circle ampli-
fication to strengthen the signals, if needed. We foresee that if Y-BLISS performs 
well, for the first time we can directly and precisely visualize and quantify DSBs 
at a single cell level, which can be combined with genome-wide single-cell BLISS 
(once optimized) and immunofluorescence to better understand the cell-to-cell 
variability in the fragility landscape and DNA repair outcomes. 
2.4.2 CUTseq and its application for CNAs profiling
CNAs associated with genomic instability are considered to play critical roles in 
driving cancer initiation, evolution, drug resistance, and a source of cell-to-cell 
genetic heterogeneity115. Thus, the ability to accurately detect and evaluate CNAs 
is critical in order to identify their origins, their role in cancer pathogenesis, under-
standing their implications for patient prognosis, and developing novel therapeutics. 
In Paper III, we presented CUTseq, as a technology for CNA profiling in cell lines 
and FFPE samples.
We used CUTseq as a reduced genome representation method, which employs 
frequent cutter restriction enzyme gDNA digestion combined with next-genera-
tion sequencing to generate sequence data adjacent to the restriction cut sites. In 
similarity to other restriction-enzyme based reduced-representation sequencing 
methods, CUTseq targets a small fraction (1%–5%) of the genome, thus provid-
ing advantages over whole-genome sequencing, such as reduced sequencing cost, 
greater depth of coverage per locus, and through multiplexing large numbers of 
samples the cost is even further reduced. 
Despite the fact that CUTseq allows for accurate CNAs calling at high resolu-
tion, it is limited to detect SNVs at any position along the genome. However, we 
demonstrated that CUTseq can reproducibly detect a considerable fraction of high-
confidence SNVs that were also detected by a standard exome capture method. 
Comparing CUTseq to another similar reduced representation genome sequencing 
method, RAD-seq144, which is used in population genetics and ecology, CUTseq 
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needs only one ligation event to barcode gDNA, while in RAD-seq two ligation 
events are required. The one-step ligation procedure likely makes the probability 
of proper ligation for a given gDNA fragment higher than with RAD-seq, although 
we did not perform a side-by-side comparison of these two technologies. In relation 
to this, CUTseq is advantageous in the case of working with low-input material 
and fragmented DNA that are extracted from FFPE tissue sections, whereas RAD-
seq typically starts with relatively high genomic DNA input before digestion144. 
Furthermore, as in CUTseq and its high-throughput format that we described in the 
paper, a single library can be prepared from hundreds of samples pooled together, 
it offers a streamlined and cost-effective way of analysis of many specimens in 
population genomics and ecology application as well. 
One application for reduced representation exome sequencing is in multi-region 
tumor sequencing, through which one can compare profiles of CNAs and SNVs 
from multiple regions in the same tumor, in order to improve the phylogenetic 
reconstruction of tumor evolution. We demonstrated that CUTseq can be used to 
assess CNA profiles of multiple-small regions of a single FFPE tissue sections 
of primary and metastatic breast cancer lesions. and also, the extent of genetic 
intratumor heterogeneity can be revealed with this approach, while most likely 
CNA analysis of gDNA extracted from larger tissue regions might otherwise go 
undetected. Importantly, due to the lower cost of multiplexed CUTseq libraries 
generated from multiple small regions of FFPE tissue sections, it can be adopted 
as a routine diagnostics tool for assessing CNAs and genetics intratumor hetero-
geneity in tissue sections that have been used for pathological tests. 
Another application of high-throughput CUTseq outside of tumor sequencing can 
be CNAs profiling for cell line authentication and genetic screens. For instance, as 
CRISPR systems can cause unwanted mutations such as large deletions and complex 
rearrangements127,145, CUTseq can be used to detect these nuclease-induced CNAs. 
In addition, high-throughput CUTseq can be greatly beneficial for authentication 
and monitoring genomic stability of cell lines in public repositories. Although, in 
this study we only used single-end sequencing and short reads, using a frequent 
cutter restriction enzyme, or a cocktail of different enzymes combined with paired-
end sequencing and longer reads would most likely enable higher exome coverage. 
An important aspect worth considering is that many traditional methods, such as 
comparative genomic hybridization (CGH) and single-nucleotide polymorphism 
(SNP) arrays use population-based averaging for SNV/CNA identification within 
pooled samples. But this approach is unable to accurately assess and unveil the 
cell-to-cell genetic heterogeneity contained within the pooled samples146. Although, 
using CUTseq for multi-regional sequencing we strived to retrieve as small as pos-
sible tissue sub-regions, but we remain unable to provide single-cell resolution. In 
relation to this, single-cell whole-genome sequencing (scWGS) from individual 
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cells has become the default choice to survey the landscape of SNVs/CNAs for 
a deeper understanding of the genetic diversity and tumor heterogeneity of each 
individual cells147–149. However, the high cost of sequencing is still a major applica-
tion drawback of scWGS, albeit with the decreasing cost of sequencing this may 
not be a problem in the future. Therefore, an important alternative would be to 
implement reduced-representation technologies, such as CUTseq as a cost-efficient 
choice in single-cells for CNAs profiling. In addition, as spatial context is typically 
lost in single-cell sequencing approaches, CUTseq combined with laser-capture 
microdissection (LCM) can potentially be a powerful tool to identify CNAs in 
specific histological tumor subtypes. 
In summary, this thesis highlighted the development and applications of novel 
genome-wide technologies to profile the landscapes of DSBs and CNAs. We envi-
sion that future technology development with integrative approaches – for example 
combination of DSB detection assays (e.g., BLISS) with, for instance, methods 
to assess genetic alterations (e.g., CUTseq) and concurrent local key epigenetic 
features or 3D genomic neighborhood and RNA expression – ideally simultane-
ously in the same sample and preserving it for downstream microscopy analysis 
(although seems challenging and very difficult to implement) can broaden our 
understanding of genomic instability and how their landscapes are shaped and or 
shape the underlying transcriptome, repair choice, epigenome, and 3D genome 
architecture. 
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